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Reactive oxygen species (ROS), including hydroxy! radical ('OH), hydrogen 
peroxide (H2O2), superoxide anion radical (O2"), singlet oxygen ('O2) and peroxyl 
radicals are generated during various metabolic and biochemical reactions. They are 
well known to be cytotoxic and have been implicated in the etiology of a number of 
human diseases. 
Among these radicals, hydroxyl radical is an extremely reactive oxidizing 
species that reacts with cell biomolecules. It is formed in normal metabolism as well as 
through the action of many drugs, poisons and radiation. Excess generation of reactive 
oxygen species have the ability, either directly or indirectly, to damage proteins, DNA 
and other biomolecules. Infact, protein are the major target for free radical attack, 
especially damaging in this respect is the hydroxyl radical. 
Human serum albumin (HSA) is the most abundant serum protein whose redox 
modification modulates its physiologic functions, as well as serves as biomarker of 
oxidative stress. It has been well documented that HSA is quite vulnerable to reactive 
oxygen species. Therefore, it is continuously exposed to oxidative stress, so that 
alterations of the conformation and function of HSA could occur, resulting in 
modification of its biological properties. Many studies show the presence of elevated 
levels of oxidized albumin, in patients with diabetes mellitus, ageing, patients with 
chronic hepatitis C. Oxidized albumin is a reliable marker of oxidative stress in 
hemodialysis patients. Alteration of redox state of HSA is also seen in patients under 
anesthesia and invasive surgery and many other diseases. 
Systemic lupus erythematosus is a multisystem chronic, autoimmune disease 
encompassing a spectrum of diseases defined by clinical criteria. Both cell mediated 
and humoral autoreactivity precipitates SLE. One of the characteristic of SLE is a long 
term high affinity immune response to self antigens. Despite the power of modern 
molecular approaches and persisting investigative efforts, lupus remains an enigmatic 
disorder or the agent (or agents) triggering this autoimmune response remains to be 
identified. Patients with SLE have a diverse array of anti-nuclear autoantibodies, but the 
cellular and molecular mechanisms that are responsible for the production of anti-
nuclear antibodies in this disease and the way in which these antibodies participate in 
tissue destruction remain highly controversial. 
Cancer development is a multistage process and has a multifactorial etiology 
which includes both genetic and environmental factors. It is suggested that ROS play a 
role in human cancer development. Protein oxidation, DNA and lipid peroxidation 
posses a major impact in carcinogenesis. Furthermore, ROS can modulate the activity of 
the proteins that respond to stress and which regulate genes that are involved in cell 
proliferation and apoptosis. Oxygen is needed for survival, but constant attack on 
protein by ROS may lead to cancer development. Understanding the mechanism by 
which these chemical changes relates to alteration in gene expression may lead to new 
concepts and novel way of preventing cancer. 
Oxidative stress plays an important role in the onset of diabetes mellitus as well 
as in diabetes associated complications. Hyperglycemia increases the production of 
ROS and decreases their scavenging by a number of mechanisms. It is well documented 
that increased oxidative stress in diabetic patients lead to protein oxidation. 
In the present study, commercially available human serum albumin was 
modified with hydroxy! radical, generated by UV irradiation of hydrogen peroxide. The 
hydroxyl radical induced modification referred as ROS modification in HSA was 
analyzed by various techniques. ROS-modified HSA resulted in UV hyperchromicity as 
compared to its native analogue. Increase in the ellipticity values of ROS-damaged 
HSA in far and near UV region of circular dichroic spectrum indicating a substantial 
loss of secondary as well tertiary structure of HSA. Oxidation of tryptophan residue 
(Trp-214) and conformational changes in domain-Il of HSA was observed by a marked 
decrease of tryptophan fluorescence intensity. SDS-PAGE under reducing and non-
reducing conditions further reiterate, the ROS-modification of HSA. Thermal 
denaturation profile showed ROS-HSA was more stable than its native form. Isoelectric 
point of HSA was changed upon ROS modification as evident by HPLC anion 
exchange analysis. Oxidation in HSA upon ROS-modification was further ascertained 
by the estimation of protein carbonyl contents. 
Native and ROS-HSA were used to induce antibodies in rabbits and were found 
to be immunogenic inducing high titre antibodies. The ROS-modified HSA was more 
immunogenic as compared to native HSA. The antigenic specificity of the induced 
antibodies was studied by competition ELISA. The immunogens showed a high degree 
of specificity towards the respective induced antibodies. Affinity purified immune IgG 
showed higher specificity as compared to serum. Experimentally induced antibodies 
against ROS-HSA exhibited polyspecificity. Various nucleic acid conformers were 
found to be effective inhibitors of induced antibody-immunogen interaction. Induced 
antibodies against native HSA showed negligible binding to the nucleic acid 
conformers. Increased immunogenicity of oxygen free radical modified HSA and the 
polyspecificity of induced antibodies against ROS-HSA towards nucleic acid 
conformers, could be co-related to a feature of SLE. 
A group of SLE sera (n=59) with high anti-DNA antibody titre were 
investigated for their specificity towards ROS-modified and native HSA, whereas 
ctDNA and plasmid DNA were used as immunochemical markers for SLE. Fifty two 
percent sera showed preferential binding to ROS-HSA in comparison to native HSA 
(p<0.001) as assessed by direct binding ELISA. Inhibition ELISA reiterated the direct 
binding results. Normal human sera (n=22) showed negligible binding with either 
antigen. Gel retardation assay further substantiated the binding of ROS-modified HSA 
with SLE autoantibodies. The apparent binding affinity of an SLE IgG calculated by 
Langmiur plot showed substainted higher constant in case of ROS-HSA. Level of 
protein oxidation in SLE was also estimated by carbonyl contents determination. 
Protein carbonyl contents were found to be significantly higher (p<0.0\) in total SLE 
serum proteins as compared with normal healthy human serum proteins. Similar results 
were obtained with isolated HSA from SLE patients and from normal subjects. 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and ROS modified HSA. For the study, sera of various patients with stomach, 
oral, lung, CML, bladder, prostate and hepatocellular carcinoma were screened. Most of 
the cancer sera showed greater recognition to ROS-HSA over native HSA (p<0.05) as 
revealed by direct binding ELISA. The binding specificity of antibodies in these sera to 
native and modified HSA was assessed by competitive binding assay. The higher 
binding to ROS-modified HSA over native HSA by most of the serum samples suggests 
the involvement of oxygen free radical modified HSA in the production of 
autoantibodies in cancer patients. Estimated carbonyl contents of total serum protein of 
cancer patients and isolated HSA from cancer patient further substainted HSA free 
radical modification. 
Thirty one type 1 diabetes mellitus sera were studied for their recognition to 
native and ROS-modified HSA. Of these, seventeen sera showed strong binding to 
ROS-HSA over native HSA (p<0.05) by direct binding ELISA. This preference was 
confirmed by inhibition ELISA. Oxidative stress in albumin of diabetes patients was 
further confirmed by carbonyl contents estimation of total serum protein and isolated 
HSA from diabetes patients. These studies point out to the fact that free radicals may 
contribute widely to autoantibodies production in type 1 diabetes mellitus. 
In conclusion, the hydroxyl radical caused extensive damaged to HSA altering 
its immunogenicity. The antibodies against modified HSA are polyspecific in nature, 
resembling the antigen binding characteristics of circulating SLE autoantibodies. It is 
postulated that hydroxyl modified HSA may play a role in the production of type 1 
diabetes autoantobodies. The possibility of hydroxyl radical modified HSA in 
autoimmunity and carcinogenesis have been indicated. 
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Abstract 
Reactive oxygen species (ROS), including hydroxyl radical (OH), hydrogen 
peroxide (H2O2), superoxide anion radical (02'"). singlet oxygen ('O2) and peroxyl 
radicals are generated during various metabolic and biochemical reactions. They are well 
known to be cytotoxic and have been implicated in the etiology of a number of human 
diseases. 
Among these radicals, hydroxyl radical is an extremely reactive oxidizing species 
that reacts with cell biomolecules. It is formed in normal metabolism as well as through 
the action of many drugs, poisons and radiation. Excess generation of reactive oxygen 
species have the ability, either directly or indirectly, to damage proteins, DNA and other 
biomolecules. Infact, protein are the major target for free radical attack, especially 
damaging in this respect is the hydroxyl radical. 
Human serum albumin (HSA) is the most abundant serum protein whose redox 
modification modulates its physiologic functions, as well as serves as biomarker of 
oxidative stress. It has been well documented that HSA is quite vulnerable to reactive 
oxygen species. Therefore, it is continuously exposed to oxidative stress, so that 
alterations of the conformation and function of HSA could occur, resulting in 
modification of its biological properties. Many studies show the presence of elevated 
levels of oxidized albumin, in patients with diabetes mellitus, ageing, patients with 
chronic hepatitis C. Oxidized albumin is a reliable marker of oxidative stress in 
hemodialysis patients. Alteration of redox state of HSA is also seen in patients under 
anesthesia and invasive surgery and many other diseases. 
Systemic lupus erythematosus is a multisystem chronic, autoimmune disease 
encompassing a spectrum of diseases defined by clinical criteria. Both cell mediated and 
humoral autoreactivity precipitates SLE. One of the characteristic of SLE is a long term 
high affinity immune response to self antigens. Despite the power of modern molecular 
approaches and persisting investigative efforts, lupus remains an enigmatic disorder or 
the agent (or agents) triggering this autoimmune response remains to be identified. 
Patients with SLE have a diverse array of anti-nuclear autoantibodies, but the cellular and 
molecular mechanisms that are responsible for the production of anti-nuclear antibodies 
in this disease and the way in which these antibodies participate in tissue destruction 
remain highly controversial. 
Cancer development is a multistage process and has a multifactorial etiology 
which includes both genetic and environmental factors. It is suggested that ROS play a 
role in human cancer development. Protein oxidation, DNA and lipid peroxidation posses 
a major impact in carcinogenesis. Furthermore, ROS can modulate the activity of the 
proteins that respond to stress and which regulate genes that are involved in cell 
proliferation and apoptosis. Oxygen is needed for survival, but constant attack on protein 
by ROS may lead to cancer development. Understanding the mechanism by which these 
chemical changes relates to alteration in gene expression may lead to new concepts and 
novel way of preventing cancer. 
Oxidative stress plays an important role in the onset of diabetes mellitus as well as 
in diabetes associated complications. Hyperglycemia increases the production of ROS 
and decreases their scavenging by a number of mechanisms. It is well documented that 
increased oxidative stress in diabetic patients lead to protein oxidation. 
In the present study, commercially available human serum albumin was modified 
with hydroxyl radical, generated by UV irradiation of hydrogen peroxide. The hydroxyl 
radical induced modification referred as ROS modification in HSA was analyzed by 
various techniques. ROS-modified HSA resulted in UV hyperchromicity as compared to 
its native analogue. Increase in the ellipticity values of ROS-damaged HSA in far and 
near UV region of circular dichroic spectrum indicating a substantial loss of secondary as 
well tertiary structure of HSA. Oxidation of tryptophan residue (Trp-214) and 
conformational changes in domain-II of HSA was observed by a marked decrease of 
tryptophan fluorescence intensity. SDS-PAGE under reducing and non-reducing 
conditions further reiterate, the ROS-modification of HSA. Thermal denaturation profile 
showed ROS-HSA was more stable than its native form. Isoelectric point of HSA was 
changed upon ROS modification as evident by HPLC anion exchange analysis. Oxidation 
in HSA upon ROS-modification was further ascertained by the estimation of protein 
carbonyl contents. 
ni 
Native and ROS-HSA were used to induce antibodies in rabbits and were found to 
be immunogenic inducing high titre antibodies. The ROS-modified HSA was more 
immunogenic as compared to native HSA. The antigenic specificity of the induced 
antibodies was studied by competition ELISA. The immunogens showed a high degree of 
specificity towards the respective induced antibodies. Affinity purified immune IgG 
showed higher specificity as compared to serum. Experimentally induced antibodies 
against ROS-HSA exhibited polyspecificity. Various nucleic acid conformers were found 
to be effective inhibitors of induced antibody-immunogen interaction. Induced antibodies 
against native HSA showed negligible binding to the nucleic acid conformers. Increased 
immunogenicity of oxygen free radical modified HSA and the polyspecificity of induced 
antibodies against ROS-HSA towards nucleic acid conformers, could be co-related to a 
feature of SLE. 
A group of SLE sera (n=59) with high anti-DNA antibody titre were investigated 
for their specificity towards ROS-modified and native HSA, whereas ctDNA and plasmid 
DNA were used as immunochemical markers for SLE. Fifty two percent sera showed 
preferential binding to ROS-HSA in comparison to native HSA (p<0.00\) as assessed by 
direct binding ELISA. Inhibition ELISA reiterated the direct binding results. Normal 
human sera (n=22) showed negligible binding with either antigen. Gel retardation assay 
further substantiated the binding of ROS-modified HSA with SLE autoantibodies. The 
apparent binding affinity of an SLE IgG calculated by Langmiur plot showed substainted 
higher constant in case of ROS-HSA. Level of protein oxidation in SLE was also 
estimated by carbonyl contents determination. Protein carbonyl contents were found to be 
significantly higher (p<0.01) in total SLE serum proteins as compared with normal 
healthy human serum proteins. Similar results were obtained with isolated HSA from 
SLE patients and from normal subjects. 
Similarly, cancer sera were screened for the presence of antibodies reactive with 
native and ROS modified HSA. For the study, sera of various patients with stomach, oral, 
lung, CML, bladder, prostate and hepatocellular carcinoma were screened. Most of the 
cancer sera showed greater recognition to ROS-HSA over native HSA (p<0.05) as 
revealed by direct binding ELISA. The binding specificity of antibodies in these sera to 
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native and modified HSA was assessed by competitive binding assay. The higher binding 
to ROS-modified HSA over native HSA by most of the serum samples suggests the 
involvement of oxygen free radical modified HSA in the production of autoantibodies in 
cancer patients. Estimated carbonyl contents of total serum protein of cancer patients and 
isolated HSA from cancer patient further substainted HSA free radical modification. 
Thirty one type 1 diabetes mellitus sera were studied for their recognition to 
native and ROS-modified HSA. Of these, seventeen sera showed strong binding to ROS-
HSA over native HSA (p<0.05) by direct binding ELISA. This preference was confirmed 
by inhibition ELISA. Oxidative stress in albumin of diabetes patients was further 
confirmed by carbonyl contents estimation of total serum protein and isolated HSA from 
diabetes patients. These studies point out to the fact that free radicals may contribute 
widely to autoantibodies production in type I diabetes mellitus. 
In conclusion, the hydroxyl radical caused extensive damaged to HSA altering its 
immunogenicity. The antibodies against modified HSA are polyspecific in nature, 
resembling the antigen binding characteristics of circulating SLE autoantibodies. It is 
postulated that hydroxyl modified HSA may play a role in the production of type 1 
diabetes autoantobodies. The possibility of hydroxyl radical modified HSA in 
autoimmunity and carcinogenesis have been indicated. 
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Introduction 
The mammalian immune system functions through complex interaction 
between various cells and their products. Antigen specific responses by the immune 
system are effected by B and T lymphocytes; T cells mediate cellular immunity (for 
example, graft rejection) and B cells mediate humoral immunity (antibody 
production). Other cell types such as macrophages and natural killer cells act non-
specifically to eliminate foreign elements. Discrimination between self and non-self jwrf is 
an important feature of the immune system. Normally, immunologic attack is directed 
against agents which are foreign such as bacteria, viruses, parasites and some internal-
changes, while it does not respond to self antigens. Since the early studies of Ehrlich. 
immunologist have demonstrated the presence of autoantibodies in the sera of patients 
with various diseases. A hallmark of most autoimmune diseases is the presence of 
autoantibodies against self antigens. 
Human Serum Albumin 
Human serum albumin (HSA) is the most abundant plasma protein 
synthesized exclusively in the liver. HSA constitutes over half of the total plasma 
protein, a concentration of 35-50 g/L, in a healthy individual (Peters, 1996). It is a 
globular protein consisting of a single peptide chain of 585 amino acids, this globular 
protein of 66.5 KDa contains 18 tyrosine, 6 methionines, 1 tryptophan, 17 disulfide 
bridges and 1 free cysteine. It does not contain any carbohydrate or any other non-
protein moiety (Peters, 1985). It consists of three homologous domains. Each domain 
can be divided into two subdomains A and B, which are formed from six and four a-
helical, respectively. HSA is characterized by high a-helical content and a large 
number of disulfide bonds. Despite very high stability, HSA is a flexible protein with 
the 3D structure susceptible to environmental factors such as temperature, pH etc. 
(Peters, 1996). HSA as the major soluble proteins constituent of the circulatory 
system, it has raany physiological and pharmacological functions. One of its main 
functions is to regulate plasma osmotic pressure between the blood and tissues and it 
is chiefly responsible for maintenance of blood pH. Another very important role of 
HSA is that it also functions as a transport molecule. This role is based on albumin, 
unequal ability to bind a variety of exogenous and endogenous compounds, such as 
metal cations, fatty acids, amino acids and diverse drug molecules (Doumas and 
Peters, 1997; Kragh-Hansen, 1981; Liu et al., 2004). HSA is also proposed to serve an 
antioxidant function in vascular compartment because of its scavenging of reactive 
oxygen and nitrogen species that are generated by basal aerobic metabolism as well as 
produced at increased rates during inflammation (Halliwell and Gutteridge, 1990; 
Halliwell, 1988). Several excellent reviews (Foster, 1960; Peters, 1980; 1985; 1992; 
Kragh-Hansen, 1981; 1990; Carter and Ho, 1994) and book (Peters, 1996) on serum 
albumins summarizing studies carried out on this protein have approved in the last 
few decades. 
Many clinical and statistical studies have shown that hypoalbuminemia is the 
strongest clinical indicator of progression of many human diseases including cancer 
(Blade et al., 1989; Chen and Magalhaes, 1990), diabetes (Murtiashaw et ai, 1983), 
rheumatic diseases (Niwa et al., 1990), Liver and other diseases. Serum albumin 
concentration reflects the nutritional condition of patients with chronic renal 
dysfunction, and the level of albumin mRNA in the liver was reported to decrease 
with the progression of renal failure (Yokozawa et ai, 1994). Quantitative as well as 
qualitative changes of serum albumin have also been suggested (Hayakawa et ai, 
1997; Hayashie/fl/., 2000). 
HSA is composed of human mercaptalbumin (HMA, reduced form) and non-
mercaptalbumin (HNA, oxidized form), that is, a protein redox couple. HMA has one 
free sulflrydryl group in position 34(Cys-34) and forms the largest fraction of free 
sulfliydryl in sera. On the other hand, HNA is composed of at least three types of 
compound and the major HNA compound is a complex of disulfide and cystein [HNA 
(Cys)] or glutathione [HNA (Glut)]. The other is an oxidation product with an 
oxidation number higher than those of mixed disulfides which are extremely small in 
proportion in extracellular fluids [HNA (Oxi)] (Era et al., 1989; Sogami et al., 1984; 
1985a; 1985b). An important physiological function of serum albumin is the 
maintenance of the redox state of the extracellular milieu via the mercapt-nonmercapt 
conversion. 
Albumin Under Oxidative Stress 
Serum albumin is the most abundant serum protein whose redox modification 
modulates its physiologic function, as well as serves as biomarker of oxidative stress 
(Fabisiak et al, 2002). In vitro oxidation of amino acid residues leads to protein 
degradation, aggregation, and cross-linking. In constant, significant evidence for the 
presence of ROS-mediated protein damage in vivo and its possible clinical 
significance is not currently available. Many studies show the presence of elevated 
levels of oxidized albumin, in patients with diabetes mellitus type 1 (Oettl et al, 
2005) and type 2 (Suzuki et al, 1992; Oettl et al., 2005), aging (Oettl et al, 2005; 
Era et al, 1995), patients with chronic hepatitis C (Rigamonti et al., 2003; Jain et al., 
2002), oxidized albumin is a reliable marker of oxidative stress in hemodialysis 
patients (Mera et al., 2005; Soejima et al, 2004) and alterafion of redox state of HSA 
is also seen in patients under anesthesia and invasive surgery (Hayakawa et al., 1997) 
and many other diseases. 
It has been well documented that HSA is quite vulnerable to reactive oxygen 
species (Davies, 1987; Anraku et al, 2001; Carballal et al, 2003). 
Therefore, HSA is continuously exposed to oxidative stress, so that alterations of the 
conformation and function of HSA could occur, resulting in modification of its 
biological properties. 
Antigenicity of Serum Albumin 
Albumin is a good antigen. Titers of 5 mg of antibody per ml of antiserum are 
readily raised in rabbits. As a result, albumin was a popular model for immunologists 
even before Michael Heidelberger conducted an elegant study of the precipitation 
reaction in 1938, which showed that the molar ratio of BSA to antibody (IgG) at the 
equivalence point was 4:1. Among more uses are the study of the kinetics of antigen-
antibody reactions (Olson et al., 1989), optimization of procedures for antibody 
production, and coupling of studies for antibody productions, now a major industry in 
the field of immunoassay. The extensive reviews of the immunochemistry of albumin 
(Habeeb, 1979) and of its immunology (Benjamin et al, 1984) are worth reading. 
With the advent of monoclonal antibodies and monovalent Fab fragments, it 
become possible to identify particular sites by inhibition or blocking techniques that 
avoid the steric problems of aggregation with precipitin. Nineteen monoclonal 
antibodies have recognized thirteen epitopes on HSA (Doyen et al., 1985). This is 
consistent with the maximum number of sites predicted by precipitin analysis, and 
suggests that about a third of the surface of an albumin molecule is antigenic. 
Cleavage of a protein into fragments would be expected to expose new 
potential determinants that were hidden in the native molecule. Albumin is no 
exception (Ishizaka et al, 1960). Denaturation by reduction (Goetzl and Peters, 1972) 
or other means (Maurer, 1959) revealed new antigenic sites. 
Clinical Implications of Albumin Antigenicity 
Antigenicity of HSA in Lacnnec's Cirrhosis and Chronic Acute Hepatitis 
Autoantibodies to normal human albumin are frequently observed in liver 
disease (Tamura et al, 1982; Peters, 1996). Usually of IgA class, they are seen most 
often with Laennec's cirrhosis (40% of cases studied) and chronic active hepatitis. It 
is not clear why this prevalent extracellular protein becomes antigenic; because IgA 
antibodies are associated with secretions. Hauptmann and Tomasi (1974) suggested 
that the autoantibodies are formed against albumin altered during metabolism in the 
GI tract. In patients infected with HBV, spontaneous secretion of IgG anti HSA 
antibodies has been reported (Hellstrom and Sylvan, 1989; Peters, 1996). Their 
production was shown to be regulated by T lymphocytes sensitized to HBV surface 
antigens plus HSA (Peters, 1996). 
Antigenicity of HSA in Diabetes 
Anti-HSA antibodies have been observed in diabetes (Eilat et al., 1981), a five 
fold greater occurrence than in nondiabetic persons (Gregor et al, 1986). Sera from 
patients with familial dysautonomia contain high levels of anti-HSA antibodies 
(Chapman et al, 1993), suggesting that they contribute to the pathological changes in 
this condition. 
Antigenicity of Albumin in Rheumatic Diseases 
In rheumatic diseases albumin levels in serum tend to be low, correlating with 
the occurrence of juxtaarticular erosions or peptic ulcer (Niwa et al, 1990). If the 
albumin gains access to normally protected areas, it can contribute to inflammation. 
Along with IgG, albumin has been identified, bound by S-S bonds to keratin sulfate-
rich proteoglycans, in the articular cartilage of patients with arthritis (Mannik and 
Person, 1993). 
Antigenicity of Albumin in Malaria 
A highly acidic nine-amino acid antigenic unit on the malaria parasite, 
Casimodium falciparum, antigen 11.1, will generate antibodies that also react with 
human albumin (Mercereau-Puijalon et al, 1992). The cross reaction may not be 
merely a chance phenomenon, but a device to assist the parasite to espace immune 
countermeasures in a manner reminiscent of the binding of albumin by Streptococcal 
protein G (Peters, 1996). 
Antigenicity of HSA in Cancer 
The marked depression of the circulating albumin level in the presence of 
progressive malignancy has been recognized since at least 1950 (Mider et al, 1950). 
Hypoalbuminemia as a prognostic aid in various common types of cancer. In several 
clinical studies HSA was the most significant single marker (Peters, 1996). Before 
1996, five reported cases of monoclonal protein produced by myelomas had anti-HSA 
immune specificity, presumably a random occurrence. Of these two were of IgA and 
three of IgG class, detectable as circulating antigen-antibody complexes; one of the 
IgA complexes was attached to HSA by S-S bonds (Eilat et al, 1981). Two of the 
HSA-IgG complexes acted as cryoglobulins, precipitating in the cold, and could 
readily be crystallized (Jentoft et al, 1987). They contained HSA/IgG-A, in the ratio 
2:1, and sedimented at 12.5 S. The antigenic site on the HSA was believed to be 
calcium dependent because citrate prevented complex formation (Peters, 1996). 
Antigenicity of Drugs-HSA Complex 
Other albumin-related antibodies are seen in drug allergies (Peters, 1996). 
Which has been extensively studied (Trynda-Lemiesz, 2004; He et al, 2005; Tang et 
al, 2005). Drug-albumin complexes can be identified by the "tailing albumin" 
phenomenon on electrophoresis of sera from patients who received prolonged 
treatment with nitrofurantonin (Wager and Teppo, 1978) or by the more rapidly 
moving albumin seen with penicillin allergy (Lafaye and Lapresle, 1988). In these 
cases the drug has apparently acted as a hapten after covalently coupling to HSA 
(Peters, 1996). 
Free Radical Biochemistry 
Free radicals are chemical species that possess an unpaired electron in the 
outer shell of the molecule. These are highly reactive (Halliwell and Gutteridge, 1989) 
and have extremely short half lives. They quickly react with other compounds, trying 
to capture the needed electron to gain stability. Generally free radical attack the 
nearest stable molecule, stealing its electron. When the attacked molecule loses its 
electron, it becomes a free radical itself, beginning a chain reaction. Once the process 
is started it can cascade, finally resulting in the disruption of a living cell. 
Free radicals are produced continuously in cells either as by products of 
metabolism or deliberately as in phagocytosis (Cheeseman and Slater, 1993). Some 
free radical arise normally during metabolism. Sometimes the body's immune 
systems cells create them to neutralize viruses and bacteria. However, environmental 
factors such as pollution, radiation, cigarette smoke and herbicides can also spawn 
free radicals Table 1 lists some sources of oxidative stress. 
Free radicals can be generated both in vivo and in vitro by one of the following 
mechanisms: 
1. Hemolytic cleavage of a covalent bond, in which a normal molecule 
fragments in two, each fragment retaining one of the paired electrons (Von 
Sonntag, 1987). Hemolytic cleavage occurs less commonly in biological 
systems, as it requires high energy input from ultraviolet light, heat or 
ionizing radiation. 
2. Loss of single electrons from a normal molecule. 
3. Addition of electron to a normal molecule. 
TABLE 1 
Source of oxidative stress in human pathophysiology 
Sources of ROS 
Mitochondrial respiratory 
chain, activated leukocytes. 
indoor and outdoor air 
(cigarette smoke, radon. 
ozone), ultraviolet light, etc. 
Oxidative 
Damage to: 
DNA 
Lipids 
Proteins 
Causal Contribution to: 
Cancer, aging, heart disease, 
Alzheimer's disease, 
inflammatory-immune injuries / 
autoimmune diseases (lupus. 
diabetes, rheumatoid arthritis), 
AIDS, adult respiratory distress 
syndrome, etc. 
Adapted from: The American Journal of Medicine, Vol. 97, pg. 3A-7S, 1994 by 
Excerpta Medica Inc. 
Free radicals can be negatively charged, positively charged or electrically neutral 
(Cheeseman and Slater, 1993). The most important free radicals in the body are the 
radical derivates of oxygen better known as reactive oxygen species (ROS) or oxygen 
free radicals (ORF). These include oxygen in its triplet state ( O2) or singlet state 
('O2), superoxide anion (02''), hydroxyl radical (OH), nitric oxide (NO), peroxynitrite 
(ONOO"), hypochlorous acid (HOCl), hydrogen peroxide (H2O2), alkoxyl radical 
(LO'), and the peroxyl radical (L02')-
(a) Hydroxyl Radical 
Hydroxyl radical is a highly reactive (Cheng et al., 2002) and toxic radical 
with one unpaired electron. It is formed through one electron reduction of hydrogen 
peroxide (Koppenaol and Liebman, 1984). It is highly electrophillic in nature 
(Imamura and Hirao, 1979). Thus it is a powerful oxidizing agent. It is formed in 
living cells during physiological processes or after environmental stimulation. Since it 
is a highly reactive radical, once it is formed, it will react with various biomolecules 
(Khan et al., 2005; Alam et al., 1992; Ashok and Ali, 1999; Grag and Ali, 1998; Ara 
and Ali, 1992).This then causes different biological damage eventually leading to 
many disease states. The OH readily react with a variety of biological 
macromolecules including protein, DNA, membrane lipids and cause protein-DNA 
crosslinks (Von Sonntag, 1987 a,b; Dizdaroglu, 1991; Halliwell and Aruoma, 1991; 
Ahmad et al., 2000; Cheng et al., 2002; Ahsan et al, 2003). 
Generation of Hydroxyl Radical 
Hydroxyl radical is generated in a number of ways. The first is their 
generation by the decomposition of H2O2 via the Fenton reaction (Fenton, 1894). 
Fe^^ + H2O2 • Fe^^ + OH + OH" 
Interaction of superoxide with H2O2 through the Haber-Weiss reaction (Haber 
and Weiss, 1934) also leads to the generation of OH. 
2O-2 + H2O2 ^ O2 + H2O+OH 
When water is exposed to ionizing radiations, such as X-ray and y-ray, hydroxyl 
radical is produced (Von Sonntag, 1987 c). Cell killing caused by ionizing radiation is 
mostly due to the hydroxyl radicals produced by water radiolysis (Baxton et al., 
1988). 
H2O h^ ^ HzO^ + e" aq 
verv fast 
HjO^ + HjO ^ HaO^+OH 
Photolysis is another important way to produce hydroxyl radical. UV irradiation is 
responsible for this reaction which can directly split H2O2 into two OH radicals 
(Masaki et al, 1995; Mazellier et ai, 2004). 
UV 
H2O2 • OH + OH 
Hydroxyl radicals can also be generated when the reduced forms of transition metal 
ions such as copper combine with H2O2 
Cu^ + H2O2 • Cu^ ^ + OH + OH-
Hydroxyl radical was also detected when H2O2 reacted with nitric oxide in the 
absence of transition metals (Zhu et al., 2000). 
Hydroxyl Radical in Cell Function 
It has recently been shown that hydroxyl radicals are generated under 
physiological and pathological condition and that they seem to be closely linked to 
various model of pathology putatively implaying oxidative stress. It is now 
recognized that the hydroxyl radical is well-regulated to help maintain homeostasis on 
the cellular level in normal, healthy tissues. Conversely, it is also known that virtually 
every disease state involves free radicals, particularly the most reactive hydroxyl 
radical (Cheng et ai, 2002). 
Activated neutrophils release hypochlorous acid (HOCl) and 0'2, which in 
turn forms hydroxyl radical. This is due to the cytotoxic effects of the neutrophils 
(Umeda et ai, 1985). NADH, GSH and H2O2 are involved in respiration, it is reported 
that GSH and NADH can react with H2O2 to produce hydroxyl radical, which has 
considerable biological significance (Florence, 1984). 
(b) Hydrogen Peroxide 
Hydrogen peroxide is not a free radical but falls in the category of ROS and is 
the most extensively studied oxygen metabolite (Harris, 1992). Hydrogen peroxide 
can be generated from the two electron reduction of oxygen. In biological systems, 
dismutation of superoxide by superoxide dismutase is the major source of H2O2 
(Tachon, 1989). 
202' + 2,H^ — ^ ^ 2 • H2O2+O2 
Hydrogen peroxide is an oxidizing agent that is not particularly reactive but its 
main significance lies in that it is the main source of hydroxyl radicals in the presence 
of transition metal ions (Aruoma and Halliwell, 1987; Aruoma et al., 1991). 
Hydrogen peroxide induces a broad spectrum of responses in mammalian cells 
(Davies, 1999), primarily DNA strand breaks (Contoni and Giacomoni, 1997). Protein 
kinases and phosphatases, proteins containing sulfhydryl group and lipids are also 
among the potential target (Abe et al, 1996; Hirpara et al, 2001). H2O2 may induce 
both apoptosis and necrosis (Chandra et al, 2000; Antunes and Cadenas, 2001; Yang 
et al., 2001). However, a recent study have shown that H2O2 can also exert anti-
apoptotic actions (Barbouti et al, 2002). 
(c) Superoxide 
The superoxide free radical anion is formed when oxygen is reduced by the 
transfer of a single electron to its outer shells (Florence, 1990; Harris, 1992). The 
major source of superoxide in vivo is the electron leakage that results from the 
electron transfer chain of the mitochondria. Superoxide on its own isn't particularly 
damaging. However, the superoxide radical anion appears to play a central role as 
other reactive intermediates are formed from it. Its main significance is probably as a 
source of hydrogen peroxide and as a reductant of transition metals, which are 
precursors to the formation of the lethal hydroxyl radical (Halliwell and Gutteridge, 
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1992). Its reaction with NO, which is believed to be the identity of endothelium 
derived relaxing factor, may also prove to be physiologically important. 
Reactive Oxygen Species and Protein Oxidation 
Reactive oxygen species (ROS) such as superoxide, hydrogen peroxide and 
hydroxyl radicals are continuously formed in living cells as a consequence of oxygen 
metabolism in all aerobic organisms. ROS are generated as a result of energy 
production from mitochondria (from the electron transport chain) (Fiskum, 2000), as a 
part of antimicrobial (Weiss and LoBuglio, 1982) or antiviral (Griot et ai, 1989) 
response, as well as by the detoxification reactions carried out by the cytochrome P-
450 system (Cederbaum, 1989; Schcltz et ai, 1990). Environmental agents such as 
ultraviolet light (Shen et al, 1996; Hu and Tapped, 1992) ionizing radiation, redox 
chemicals and cigarette smoke (Eiserich et al., 1995) also readily generate ROS. 
Excess generation of reactive oxygen species have the ability, either directly 
or indirectly, to damage proteins, DNA and other cell biomolecules (Shacter, 2000). 
In fact, proteins are major targets for free radical attack, especially damaging in this 
respect is the hydroxyl radical. Protein oxidation, which results in functional 
disruption, is not random but appears to be associated with increased oxidation in 
specific proteins (Poon et al, 2006). A number of studies indicate a strong role for 
increases in protein oxidation as a primary cause of cellular dysfunction observed 
during aging and age related neuro-degenerative diseases (Tabner et al., 2001) such as 
Alzeimer's disease, Parkinson's disease, and possible some other protein 
conformational diseases. Inhibition of a wide array of enzyme activities have been 
reported (Arutyunova et al., 2003). Modification of structural protein can also lead to 
loss of function. As for example, fibrinogen on exposure to ROS loses its ability to 
form a solid clot (Shacter et al, 1995). Oxidation of synovial fluid immunoglobulins 
cause aggregafion and contribute to the etiology of rheumatoid arthritis (Chou, 2002). 
Oxidatively modified LDL may play a significant role in the etiology of 
atherosclerosis (Holvoet and Collen, 1998). These disorders could be due to the 
formation of abnormal protein aggregates as a consequence of ROS damage. High 
levels of advanced oxidation products of protein have been implicated in the 
pathogenesis of chronic rheumatic valve disease (Chiu-Braga et al, 2006). Recentiy, 
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purified human 60 KDa Ro protein was found to be oxidatively modified leading to 
the formatioin of neoantigens which could in turn initiate autoimmunity (Scofield et 
al., 2005). 
ROS modification can change the structure and function of HSA. As milk 
oxidation of HSA has no detectable effect on the binding of drugs to site I in 
subdomain IIA. In contrast, both the ligand binding property of site II and the 
esterase-like activity of oxidized HSAs are decreased, most probably due to 
conformational changes in subdomain IIIA (Anraku et al., 2001). Patients with 
diabetes mellitus have elevated oxidized form of HSA compared to healthy controls 
and non-diabetic patients, respectively (Suzuki et al., 1992; Oettl et al., 2005). 
Recently, it was reported that oxidized albumin is a reliable marker of oxidative stress 
in hemodialysis patients (Mera et al., 2005). 
Protein Carbonyl Group as Biomarkers of Oxidative Stress 
Protein carbonyl content is actually the most general indicator and by far the 
most commonly used marker of protein oxidation (Berlett and Stadman, 1997; 
Chevion et al., 2000; Shacter, 2000; Heal, 2002) and accumulation of protein 
carbonyls has been observed in many human diseases including Alzheimer's disease 
(AD), diabetes, inflammatory bowel disease (IBD), rheumatoid diseases, sepsis, 
chronic renal failure, respiratory distress syndrome (Dalle-Dorme et al., 2003) and 
cancer (Yilmaz et al., 2003). 
Carbonyl (CO) group (aldehydes and ketones) are produced on protein side 
chains (especially of Pro, Arg, Lys, and Thr residues) when they are oxidized. These 
moieties are chemically stable, which is useful for both their detection and storage. 
Protein carbonyl derivatives can also be generated through oxidative cleavage of 
proteins by either the a-oxidation pathway or by oxidation of glutamyl side chains, 
leading to formation of a peptide in which the N-terminal amino acid is blocked by an 
a-ketoacyl derivative (Berlett and Stadman, 1997). In addition, CO groups may be 
introduced into proteins by secondary reaction of the nucleophilic side chains of Cys, 
His, and Lys residues, with aldehydes (Uchida, 2000). 
The usage of protein CO groups as biomarkers of oxidative stress has some 
advantages in comparison with the measurement of other oxidation products because 
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of the relative early formation and the relative stability of carbonylated proteins. Most 
of the assays for detection of protein CO group involve derivatisation of the carbonyl 
group with 2, 4-dinitrophenylhydrazine (DNPH), which leads to formation of a stable 
dinitrophenyl (DNP) hydrazine product. This then can be detected by various means, 
such as spectrophometric assay, enzyme-linked immunosorbent assay (ELISA), and 
one-dimensional or two dimensional electrophoresis followed by Western blot 
immunoassay (Dalle-Donne et al, 2003). 
The classical approach to the detection of protein carbonyl groups involves 
their reaction with DNPH followed by the spectrophotometric quantification of the 
acid hydrazones at 370 nm (Levine et al, 1990; 1994). Spectrophotometric DNPH 
method is useful to quantify carbonyl content in mixture of proteins, such as plasma, 
tissue homogenates, cellular extracts, or in isolated proteins. However, this assay has 
been shown to be very sensitive for the determination of carbonyl content in purified 
protein (Dalle-Donne et o/., 2001). Spectrophotometric DNPH assay have been used 
for the detection of carbonylated protein in many human disease (Table 2). 
Biological Antioxidants Defenses 
Aerobic organisms have potent antioxidant defences whose role is to 
neutralize and minimize the potentially cytotoxic and genotoxic effects of reactive 
oxidants. Antioxidants are key line of defence capable of scavenging free radicals by 
preventing radical formation, intercepting radicals from further activity (Cotgreave et 
al, 1998), or participating in repair of damage caused by free radicals (Sies, 1993). 
Antioxidants defences may be primary or secondary. The defences that directly 
scavenge, H2O2 and OH are known as primary antioxidant defence. Secondary 
antioxidant defences consist of the repair mechanism that act on biomolecules that 
have undergone oxidative damage. There may be enzymatic or non-enzymatic 
antioxidant defences. 
(i) Enzymatic Antioxidant Defences 
This group includes superoxide dimutase (SOD), catalase, glutathione 
reductase, and glutathione peroxidase (Fang et al, 2002). Superoxide dismutase 
catalyse the dismutation of O2'" to H2O2 (Fridovich, 1989). 
TABLE 2 
Spectrophotometric DNPH assay used for the detection of carbonylated protein in 
human diseases 
Diseases References 
Alzheimer's disease 
Amoyotrophic lateral sclerosis 
Blabber cancer 
Cataractogenesis 
Chronic hepatitis C 
Cystic fibrosis 
Diabetes 
Inflammatory bowel disease 
Juvenile chronic arthritis 
Newborn infants at risk of chronic lung disease 
Rheumatoid arthritis 
Smokers 
Systemic amyloidosis 
Uremia 
Varicocele 
Smith era/., 1991 
Bowling et al, 1993; Ferrante et al, 1997 
Yilmaz et al, 2003 
Boscia et al., 2000 
DeUaria etal., 1996 
McGrath et al., 2000; Range et al., 1999 
Telci etal., 2000; Dominguez et at., 1998 
Lih-Brody e? a/., 1996 
Renke et al., 2000 
Varsila er fl/., 1995 
Mantle era/., 1999 
Marangone/a/., 1999 
Ando etal., 1997 
Lim et al., 2002 
Chen et al., 2001 
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0 2 " + 0 2 " ^ Q ^ ^ H2O2 + O2 
The concentration of SOD is high in tissues with high oxygen utilization and is 
inducible by raising tissue p02. 
Catalase mediates the detoxification of H2O2 from the cell when it is present in 
high concentrations. The enzyme is a heme protein that decomposes H2O2 to O2 and 
H2O 
2H2O2 ^^^^^^'' , O2 + 2H2O 
Catalase is present in the cytosol, mitochondria and other organelles, but is difficult to 
detect in an extracellular environment. 
Glutathione peroxidase is a selenium enzyme, it reduces H2O2 by catalyzing 
its reaction with the reduced form of glutathione (GSH). 
Glutathione 
H2O2 + 2GSH • 2H2O + GSSG 
•, (oxidized glutathione) 
peroxidase ^ '^  ' 
Normally, most of the intracellular glutathione is in hs reduced form. Increased 
intracellular concentrations of H2O2 results in a drop in GSH/GSSG ratio, which 
serves to detect intracellular oxidative stress (Tribble and Jones, 1990). Other 
enzymatic proteins such as DT- diaphorase or epoxide hydrolase are also considered 
to be primary antioxidant defences (Ernster, 1987; Lind et ai, 1990). 
(ii) Non-Enzymatic Antioxidant Defences 
There is no enzymatic mechanism to directly protect against OH because of 
its extremely high reactivity and rapid consumption. The cell possesses non-
enzymatic antioxidant defence mechanisms, which scavenge OH and other free 
radicals. Some of these antioxidants are glutathione, arginine, citrulline, taurine, 
creatine, selenium, zinc, vitamin E, vitamin C, vitamin A, tea polyphenols etc. (Fang 
et al, 2002) exert synergistic actions in scavenging free radicals. Some of these 
scanvengers may be hydrophilic (ascorbate, urate, glutathione) or hydrophobic (a-
tocopherol, p-carotene). Vitamin E (a-tocopherol), the major lipid-soluble antioxidant 
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protects against lipid peroxidation by donating a hydrogen ion to oxygen free radical. 
The resultant tocopheryl radical may be reduced by the ascorbic acid-GSG redox 
couple (Cadenas, 1989; Empey et al, 1992). a-Tocopherol is key OH scavenges and 
chain breaking antioxidant in biological membranes (Niki et al., 1988). Vitamin E is 
important in protecting tissue from a variety of physio-pathological insults, which 
resuhs in enhanced tissue reactive oxygen species generation (Chow, 1991). (3-
carotene, the most efficient scavenger of singlet oxygen has a synergistic action with 
vitamin E (DiMascio et al, 1991). 
The various defences are complementary to each other since they metabolize 
or scavenge different species in different cellular compartments. A large body of the 
literature supports the notion that dietary antioxidants are useful radio protectors and 
play an important role in preventing many human diseases (e.g. cancer, 
atherosclerosis, stroke, rheumatoid arthritis, neurodegeneration, and diabetes) (Fang et 
al, 2002; Devasagayam et al, 2004). 
Oxidative stress occurs when the ROS exceeds the body's natural antioxidant 
defense mechanism, causing damage to biomolecules such as proteins, lipids and 
nucleic acid. Oxidative stress has been thought to contribute to the general decline in 
cellular functions that are associated with many autoimmune diseases (Kumagai et al., 
2003; Evans et al, 2000) and human cancers (Vander Logt et al, 2005; Renschler, 
2004; Mates et al, 2000; DeWease et al, 1998). 
Autoimmunity 
Autoimmunity is a state wherein the host mounts an immune response to self 
Autoimmune state includes four possible permutations. 
1. The antiidiotypic responses in normal hosts mount to modulate normal 
antibody responses, as might occur following an acute infection 
(Shoenfeld, 1996). 
2. The immune response to transformed cells that occur in patients suffering 
from malignancies or from intracellular infections (Shoenfeld, 1996). 
3. The deterimental autoimmune response in the abnormal host exemplified 
by the paraneoplastic syndrome (Lernmark, 1997). The immune response 
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to malignant cells cross reacts with normal tissue antigens causing an 
autoimmune disorder. 
4. The immune response in an otherwise normal host which results in a 
classic autoimmune, clinico-pathologic condition such as lupus, diabetes 
or thyroiditis. 
Autoreactivity appears to be a normal house keeping process within our 
immune system. It appears that T lymphocytes mature in thymus. Self peptides in the 
context of self-MHC are presented by thymic cells to immature T lymphocytes 
flowing thymus. Immature T lymphocytes engage these complexes via their T cell 
receptors (TCR). T cells which fail to recognize any complexes or which bind with 
high affinity/avidity are allowed to undergo apoptosis (negative selection) (Maggi et 
al, 2005; Aston-Richardt and Tonegawa, 1994; Nossal, 1994; Von Boehmer, 1994). 
T cells with lower affinity binding survive, exit the thymus and enter the peripheral 
circulation (positive selection). Through these and other editing processes a state of 
self tolerance is achieved (Goodnow, 1992). 
The mechanisms responsible for the transition from normal autoimmunity to 
autoimmune disease state are unknown. Epitope spreading, idiotypic network 
dysregulation and defective apoptosis (Mountz and Zhou, 2001) are few of the recent 
cause of autoimmune diseases. Delayed clearance of apoptotic cells is also a factor in 
the development of SLE (Ahsan et al, 2003). The major factors associated with the 
development of autoimmunity are genetic, immunologic, hormonal and environmental 
(Brickman and Shoenfeld, 2001). Twin studies in lupus and in RA (Criswell and 
Amos, 2000) as well as multiplex family studies involving lupus and diabetic 
(Craddock et al., 1998; Harley et ah, 2001) patients prove that autoimmune diseases 
are both multigenic and multifactorial in etiology. 
(1) Genetic Factors 
Majority of genes which have been associated with autoimmune diseases map 
within the MHC of man, or HLA region. Human lymphocyte antigen (HLA) 
molecules present on the surface of all nucleated cells are encoded for within the 
major histocomptibility complex on the short arm of chromosome 6 in humans (Klein 
and Sato, 2000). The initiation of an autoimmune response requires that the self 
reactive T cells interact with self-antigen and HLA class II antigen complex with 
sufficient avidity for the development of autoantibodies in subsequent autoimmune 
disease. The involvement of genetic factors has been linked to the HLA system, 
particular the HLA-DR sublocus. The HLA genes function as secondary genes to 
allow expression of specific autoantibody or the respective disease state (Bias et al, 
1986). For example, immunogenetic analysis of glaucoma patients showed a possible 
association betv/een HLA-DRBl 1502 allele and the patients positive for anti-bovine 
neurofilament protein light submit (anti-NF-L) autoantibodies. It suggests that the 
HLA class Il-linked gene involved in development of autoimmunity in patient with 
glaucoma (Yano et al., 2005). The association between certain autoimmune diseases 
and HLA antigen such as SLE-DR2 and DR3, Sjogren's syndrome-DR2 and DR3, 
insulin-dependent diabetes mellitus-DR4 and DR3, Grave's disease-DR3, myasthenia 
gravis-DR3 and rheumatoid arthritis-DR4, are well documented. Multiple hypothesis 
have been presented to explain how particular HLA alleles confer susceptibility to 
particular diseases (Brickman and Shoenfeld, 2001). Errors in HLA-peptide T 
lymphocyte selection in the thymus, in HLA molecules folding or in peripheral APC 
presentation of antigens in the context of particular HLA protein have been proposed 
(Colbert, 2000). 
(ii) Immunologic Factors 
Autoimmunity may be antibody or cell mediated or a combination of both. In 
the case of antibodies, B lymphocytes, although possessing receptors for self antigens 
e.g. thyroglobulins, DNA, IgG do not normally produce significant quantities of 
antibodies unless they receive T cell help. This will not, in health, be given, because T 
cells with high affinity for self determinants will have undergone apoptosis in thymus 
(Aston-Rickardt and Tonegawa, 1994; Nossal, 1994; Von Boehmer, 1994). However 
if antigen is presented in slightly altered form, or way, e.g. chemically altered or with 
upregulated MHC class II, then helper T cells may be activated. The activated T cells 
can lead to tissue destruction either by direct killing or by activating macrophages and 
a potent inflammatory response (Lorenz el al, 2001). T cells have been implicated as 
the likely primary mediator of several autoimmune diseases including type 1 diabetes 
mellitus, rheumatoid arthritis and multiple sclerosis. In a wide variety of autoimmune 
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diseases like SLE, Sjogren's syndrome, progressive systemic sclerosis, rheumatoid 
arthritis and pernicious anaemia, the regulatory failure results in a significant decrease 
in T suppressor cell numbers and activity, there by unbalancing the T-helper/T-
suppressor cell ratio (Krakauer et al., 1981). Regulatory T-cell plays an important role 
in the pathogenesis of autoimmunity and these cells are now also believed to play a 
key role in mediating transplantation tolerance and inhibiting the induction of tumor 
immunity (Choileain and Redmond, 2006). 
B cells play a paramount role in systemic autoimmunity (Zouali, 2001). B cell 
receptor signaling requires a tight regulation of several protein tyrosine kinases and 
phosphatases. Recently, a new area has been reached, whereby B lymphocytes return 
as a significant contributor to autoimmune disorders (Youinou et al., 2006) as the 
paradigm that B cell response to self antigens is promoted by antibodies has become 
unsatisfactory. Studies over the last decade have indeed revealed that B cells serve 
extraordinarily diverse functions within the immune system other than antibody 
production. They normally play a role in the development in the regulation, as well as 
the activation of lymphoid architecture, regulating dentritic cells and T cell subsets 
functions through cytokine production. Receptor editing is also essential in B cells 
and aids in preventing autoimmunity. Both abnormalities in the distribution of B cells 
subsets and clinical benefit response to B cell depletion in autoimmune states 
illustrate their importance (Youinou et al., 2006). Altered or abnormal signaling 
results in production of pathogenic autoantibodies and lupus like glomerulonephritis 
(Huck et al., 2001). Altered expression of signaling molecules in T and B 
lymphocytes from patients with human lupus suggests that the subversion of signaling 
could account for the hyperproduction of autoantibodies (Zouali, 2002). 
Aging of the immune system is another important parameter, which may 
contribute to the development of autoimmunity. Aging of the immune system, or 
immunosenescence, is characterized by changes in T cell subsets, cellular and 
molecular level alterations and thymic atrophy, resulting in a decline of T and B cell 
function. These alteration have been shown to be accompanied by a loss of ability to 
recognize "self and "foreign" antigens. Recently, it has been hypothesized that 
secondary to thymus involution with a decline in naive T cells and the accumulation 
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of memory T cells with activation owing to "neoantigen" during the aging process 
may cause the development of autoimmune conditions (Prelog, 2006). 
(iii) Hormonal Factors 
Hormones are a significant factor in the development of autoimmune disorder 
(Ahmed and Talal, 1999; Lahita, 1999). Autoimmune diseases occur for more 
commonly in females than in males, with a ratio of 10:1 or greater in certain diseases. 
Hormonal factors such as sex hormones, thymic hormones and corticosteroids play a 
significant role (Talal, 1989; Counihan et al, 1991; Lahita, 1992; Moinuddin and Ali, 
1994). Additional hormones including DHEA (Van Volhenhoven et al, 1998), 
progesterone (Van Vollenhoven and Mc Giure, 1994) and prolactin (Walker et al, 
1998) appear to have immune diseases is presently under investigation. 
(iv) Environmental Factors 
Number of environmental factors have been implicated in autoimmune 
diseases including infectious agents, medications, chemicals, toxin and ultraviolet 
light (Aharon and Shoenfeld, 1998; Saraux et al, 1999), smoking and obesity may 
increase the risk of RA (Shovman and Shoenfeld, 2000). Here, the multifactorial 
nature of autoimmune disorders also became evident while ultraviolet light is known 
to trigger lupus (McGrath, 1999), it has been very effectively used to treat psoriasis, 
another autoimmune disease (Halpern et al, 2000). D-penicillamine, a medication has 
been implicated in the development of autoimmune diseases such as lupus and 
glomerulonephritis (Brik et al., 1995). Physical and psychological stresses have also 
been implicated in the development of autoimmune diseases (Gaillard and Spinedi, 
1998). 
The common thread among all the hypotheses of autoimmune diseases is the 
loss of energy to innocent autoantigens or the loss of tolerance to self However, to 
date no single theory adequately explains the development of all autoimmune diseases 
and, at least in humans, no one theory adequately explain the development of 
particular autoimmune disorder. Therefore, it may be stated that the evolution from 
autoimmunity to autoimmune disease is multifactorial (Brickman and Shoenfeld, 
2001). 
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Autoimmiune diseases may be classified, somewhat arbitrarily, into organ 
specific and non-organ-specific (or systemic) autoimmune diseases (Table 3). In 
organ-specific autoimmune diseases, the immune response is directed to a target 
antigen unique to a single organ or gland, so that the manifestations are largely 
limited directly by humoral (antibody) or cell-mediated mechanisms. Alternatively, 
the antibodies may over stimulate or block the normal function of the target organ 
(Goldsby et ah, 2000). In systemic autoimmune diseases, the response is directed 
toward a broad range of target antigens and involves a number of organs and tissues. 
These diseases reflect a general defect in immune regulation that results in 
hyperactive T cells and B cells. Tissue damage is widespread, both from cell-
mediated immune responses and from direct cellular damage caused by auto-
antibodieds or by accumulation of immune complexes (Goldsby et al., 2000). SLE is 
a classic example of systemic autoimmune diseases. 
Systemic Lupus Erythematosus 
Systemic lupus erythematosus (SLE; also referred to as "lupus") is the most 
clinically and serologically diverse autoimmune disease. The spectrum of disease 
manifestations among patients with SLE is broad, ranging from subtle symptoms to 
life-threatening multiorgan failure. Because of its heterogeneous presentation and 
unpredictable course, clinical management of SLE remains one of the greatest 
challenges to physicians. The lack of reliable, specific biomarkers for SLE not only 
hampers precise assessment of disease activity and prompt identification of patients at 
risk for flares and organs damage, but also prohibits accurate evaluation of responses 
to treatment (Schiffenbauer et al, 2004). In short, SLE is a muhisystem autoimmune 
disorder of unknown etiology (Perl, 2004) or the agent (or agents) triggering this 
autoimmune response remain to be identified, but it is thought that a combination of 
genetic and environment factors are required (Pisetsky, 2000; Ahsan et al, 2003; Perl, 
2004). 
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TABLE 3 
Classification of some autoimmune diseases in humans 
Organ-specific autoimmune diseases 
Disease Self-antigen Immune response 
Insulin-dependent diabetes Pancreatic beta cells 
mellitus 
Addison's disease 
Autoimmune hemolytic 
anemia 
Graves' disease 
Hashimoto's thyroiditis 
Idiopathic 
thrombocytopenia purpura 
Myasthenia gravis 
Myocardial infarction 
Pernicious anemia 
Spontaneous infertility 
Adrenal cells 
RBC membrane proteins 
Thyroid-stimulating 
hormone receptor 
Thyroid protein and cells 
Autoantibodies, TDTH cells 
Autoantibodies 
Autoantibodies 
Autoantibodies 
(stimulating) 
Autoantibodies, TDTH cells 
Platelet membrane proteins Autoantibodies 
Acetylcholine receptors 
Heart 
Gastric parietal cells; 
intrinsic factor 
Sperm 
Autoantibodies (blocking) 
Autoantibodies 
Autoantibodies 
Autoantibodies 
Systemic autoimmune diseases 
SLE 
Rheumatoid arthritis 
Scleroderma 
Sjogren's syndrome 
Multiple sclerosis 
DNA, cellular protein, 
RBC and platelet 
membranes 
Connective tissue, IgG 
Nuclei, heart, lungs, 
kidney, gastrointestinal 
tract, thyroid 
Salivary gland, liver, 
kidney, thyroid 
Brain or white matter 
Autoantibodies, immune 
complexes 
Autoantibodies, immune 
complexes 
Autoantibodies 
Autoantibodies 
TDTH cells and Tc cells, 
autoantibodies 
(Adapted from: Goldsby et al., 2000) 
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SLE is characterized by the production of autoantibodies directed against 
cellular protein and nucleic acids in complex with one another and phospholipids 
(Reeves et ai, 2004; Reichlin, 2004; Eggleton, 2003). Some of these antibodies are 
responsible for the pathogenesis of the disease (Paul et ai, 1990). The binding 
diversity of lipus autoantibodies to a whole spectrum of modified nucleic acid 
conformers (Ali et al, 1991; Alam and Ali, 1992; Mam et ai, 1992; 1993; Arif e/ ai, 
1994; Arjumand and Ali, 1994; Klinman et al., 1994; Moinuddin and Ali, 1994; 
Ahmad et ai, 1997; Grag and Ali, 1998; Dixit et al., 2005; Dixit and Ali, 2004) seems 
to be enormous. Anti-DNA production accompanies many encounters with bacterial 
and viruses (Wu et ai, 1997). Analysis of sera obtained from the same patient over a 
long period of time has demonstrated that different autoantibody specificities appear 
at different time points with a general trend towards increasing the number of antigens 
recognized by the sera (Orth et a!., 1998; Greidinger and Hoffman, 2001). These 
observations, of increasing complexity of an autoimmune response over a period of 
time are very similar to those reported by Lehmann et al. in their mode of epitope 
spreading in experimental autoimmune encephalomyelitis (Lehmann et al., 1992; 
1993). Thus, it was generally accepted that intermolecular epitope spreading was one 
of the mechanisms for the amplification and diversification of autoantibody responses 
in SLE (James and Harley, 1998). It is also demonstrating the presence of 
autoanfibodies reactive with at least one SLE-associated antigen several years prior to 
clinical diagnosis has further strengthened the role of epitope spreading in lupus 
autoimmunity (Arbuckle et al., 2003). However, the serological evidence from human 
studies at best is correlative. The experimental animal model systems have clearly 
provided evidence for the occurrence of epitope spreading within SLE-associated 
antigens (Monneaux and MuUer, 2002). This study has provided certain clues 
regarding the mechanisms of autoantibody generation in systemic autoimmune 
disorders and its role in the pathogenesis of the disease. Epitope spreading in organ-
specific autoimmune diseases has been recentiy reviewed (McMahon et ai, 2005) and 
will not be discussed. Recently, epitope spreading within lupus-associated 
ribonucleoprotein antigen has been reviewed (Deshmukh et al., 2005). This review 
discusses the animal model system of epitope spreading within these 
ribonucleaprotein antigens, the mechanisms of epitope spreading, and its relevance for 
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disease pathogenesis. In an other recent study, described that purified lupus-
associated 60 KDa Ro protein was found to be oxidatively modified leading to the 
formation of neoantigens which could in turn initiate autoimmunity (Scofield et ai, 
2005). This study has reported intramolecular epitope spreading within the Ro 
molecule and intermolecular epitope spreading to La, dsDNA, nRNP and Sm. 
Clinical features of SLE can range from a simple skin rash to a rapidly 
progressive lethal muhiorgan disease involving kidneys, brain, blood vessels and 
cells, lung and heart. These patients also suffer from defective apoptosis mechanisms 
(Botto and Walport, 2002). The disease predominantly affects women with a female 
to male ratio of approximately 9:1 (Zouali, 2001). Antinuclear antibodies (ANA) are 
important markers for diagnosis and classification and thought to be involved in the 
pathogenesis of SLE (Sherer et ai, 2004). 
Autoantibodies and B cells have been in the lupus limelight for decades, but 
now T cells have been studied extensively in SLE (Spronk et al., 1996). T cells have 
been cloned from lupus-prone mice and these were found to stimulate the production 
of anti-DNA antibodies and renal lesions when injected in vivo. In mice and human, 
the histone/DNA binding T cells are activated, express the CD 40 ligand, and have the 
potential to trigger B cells to produce antibodies. A finding that T cells from MRL-
Ipr/lpr mice recognize DNA-binding peptide from a parasitic underlines the relevance 
of Rekvig's report implicating a viral DNA-binding protein (the polyoma T antigen) 
in human SLE. Perhaps many different DNA-binding peptides of microbial organ can 
be immunological carriers of nucleic acid or polynucleotide haptens. It is possible that 
the lupus patients, collective experience with microbial DNA-binding proteins builds 
up a repertoire of carrier-specific memory T cells, members of which participate in 
triggering, enhancing or modifying the activation of B cells with the capacity to 
produce anti-DNA antibodies. 
Oxygen Free Radicals in SLE 
Oxygen derived free radicals are important in both natural and acquired 
immunity. Neutrophil and macrophage phagocytosis stimulates various cellular 
processes including the "respiratory burst" whereby increased cellular oxygen uptake 
results in the production of potent oxidant bactericidal agents (Joseph, 2000) thereby 
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killing bacteria and regulating the process of acute inflammation (Halliwell 1982). 
Inflammatory response in thus advantageous for the organism. However, abnormal 
over activation of phagocytes with consequent exacerbation of reactive oxygen 
metabolites production may damage surrounding tissues and lead to diseases such as 
SLE (Proctor and Reynolds, 1984; Southern and Fowls, 1988; Halliwell and 
Gutteridge, 1989). 
Free radical-mediated damage has been implicated in the pathogenesis of SLE 
and other diseases (Serban et al, 1994; 1996; Grune et al, 1997; Michel et al, 1997; 
Turi et al, 1997; Grag and Ali, 1998; Ashok and Ah, 1998; Dixit et al, 2005; Ahsan 
et al, 2003; Dixit and Ali, 2004; Scofield et al, 2005; Khan et al, 2005; Khan and 
Ali, 2006). Reactive lipid peroxidation products have been shown to form adducts 
with lysine, histidine, and cysteine targets (Palinski and Witztam, 2000; Berliner et 
al, 1995; Steinberg, 1997; Uchida et al, 1998). One of the most common and 
reactive lipid oxidation products is 4-hydroxy-2-nonenal (HNE) (Comporti, 1998). 
Increased levels of HNE-modified proteins have been detected in the sera of children 
with autoimmune diseases (Grune et al, 1997). HNE-protein adducts are potential 
neoantigens and so could be involved in the pathogenesis of autoimmune diseases. 
Mitochondrial hyperpolarization, increased ROS production and cytoplasmic 
alkalinization plays crucial roles in altered IL-10 responsiveness in SLE (Gergely, 
2002). 
There is growing evidence for a role of oxidative stress in the etiology and 
pathogenesis of SLE (Evans, 2000). Protein is a major target for oxidants resulting in 
increased autoantigen production, enhancement of antigenicity and altered cell 
functions. For example, recently lupus-associated 60-KDa Ro protein is modified with 
the lipid oxidation product 4-hydroxy-2-noneral (HNE) increases antigenicity and 
facilitates epitope spreading (Scofield et al, 2005). 
Malignancies are more common in most autoimmune diseases as compared to 
the general population (Ramos-Casals et al, 2000). 
Cancer 
Carcinogenesis is the malignant transformation of a cell or group of cells 
(Faber and Cameron, 1980; Potter, 1983; Farber, 1984). Almost every fissue in the 
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body can spawn malignancies, some even yield several types, with each cancer having 
unique features. The genes implicated in the malignancy are often modified forms of 
the human genes. The activation of proto-oncogenes into oncogenes, the product of 
which when altered contribute to malignancy. Mutation can also convert proto-
oncogene into carcinogenic oncogenes. 
As with other chronic diseases, cancer too has a multifactorial etiology which 
include both genetic and environmental factors (Gourley et al, 1992). Genetic 
influence, though long been suspected in incidence of cancer, is less conspicuous and 
more difficult to identify (Clemens, 1991). The environmental factors are responsible 
for maximum percentage of all human cancers. Among the environmental factors 
alcohol consumption is associated with cancer of oesophagus, liver and rectum (Kabat 
et al., 1986; Eskelson et al, 1993). Tobacco consumption is the major cause of cancer 
of lung, larynx, mouth, pharynx, bladder, pancreas and probably kidney (WHO, 
1983). Dietary factors such as food additives, contaminants, high fat diet have been, 
related to cancer (Ames, 1983) viruses such or Hepatitis B and C are related to 
hepatocellular carcinoma (Blumberg et al, 1975). Occupational exposures to 
benzene, arsenic, cadmium, chromium, etc have also been known to cause cancer 
(Kasai and Nishimura, 1984; Frenkel, 1992; Kolachna et al, 1993; Lagorio et al, 
1994). Other environmental factors such as sunlight, radiations, pesticides and 
medications are also known to be related to cancer (Ananthaswamy and Pierceall, 
1990; Liehr, 1997). 
Most of the exogenous carcinogens act via production of reactive oxygen 
species (Feig et al, 1994; Erhardt et al, 1997). 
Oxygen Free Radicals in Cancer 
Cancer development is a multistage process. The cascade of molecular and 
cellular changes that occur during the process of carcinogenesis can be mediated by a 
variety of endogenous and environmental factors (Klannig and Kamendulis, 2004; 
Ames, 1983). It is suggested that ROS may play a role in human cancer development 
(Klanning and Kamendulis, 2004; Goldmein and Witz, 1990; Wiseman and Halliwell, 
1996) sources of ROS may be both exogenous (drugs, ozone, radiation) and 
endogenous (NO, phogocytes, leakage from mitochandria (Klannig and Kamendulis, 
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2004). In a review, Klannig and Kamendulis (2004) described the involvement of 
ROS in the various stages (initiation, promotion, progression) of the process of 
carcinogenesis. 
Reactive oxygen species (ROS) such as superoxide anion radical, hydroxyl 
radical, and hydrogen peroxide are produced in aerobic metabolism (Yun-Zhong et 
ai, 2002). An imbalance between the production and detoxification of ROS results in 
oxidative stress. ROS has been implicated in the pathogenesis of certain diseases, 
including cancer (Trush and Kensler, 1991; Tsai et al., 1998; Ashok and Ali, 1998; 
Taysi et al., 2003; Khan et al., 2005). Among ROS, hydroxyl radicals on the most 
reactive one, they can stimulate free radical chain reactions by interacting with 
protein, lipids and nucleic acids causing cellular damage and even diseases (Cheng et 
al., 2002), these radicals have been postulated to play a direct or indirect role in 
several pathological conditions, such as carcinogenesis and many other human 
diseases (Halliwell, 2001). Protein oxidation, DNA and lipid peroxidation posses a 
major impact in carcinogenesis (Yilmag et a\., 2003). Furthermore, ROS can 
modulate the activity of the proteins that respond to stress and which regulate genes 
that are involved in cell proliferation, differentiation and apoptosis (Wiseman and 
Halliwell, 1996). Extracellular ROS generation seems to represent a hallmark of 
transformed fibroblasts (Irani et al., 1997; Bauer, 2000). Extracellular ROS of 
transformed cells are key elements for intercellular induction of apoptosis (Herdener 
et al., 2000; Paul and Bauer, 2001; Heigold and Bauer, 2002; Schimmel and Bauer, 
2002). Although it is clear that ROS may induce cellular changes similar to those 
produced by known carcinogens (Wiseman and Halliwell, 1996), the precise 
mechanisms remain unclear. For instance it is suggested that over production of ROS, 
such as superoxide and hydrogen peroxide, by polymorphonuclear leukocytes might 
sometimes initiate carcinogenesis (Babior, 2000). Phagocytosis by polymorphonucle-
ar leukocytes results in the release of ROS, referred to as the respiratory burst, which 
plays an important role in host defense against certain microorganisms. Excessive 
generation of ROS by these phogocytes may cause harm to surrounding tissue 
(Babior, 2000). V/hen key genes or proteins responsible for intestinal cell homeostasis 
are targeted, dysplasia and subsequent development of adenoma or carcinoma may 
occur. 
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Oxygen is needed for survival, but constant attack on protein, by ROS may 
lead to cancer development. Understanding the mechanisms by which these chemical 
changes relates to alteration in gene expression may lead to new concepts and novel 
ways of preventing cancer. 
Cancer: The Serum Albumin Connection 
The marked depression of the circulating albumin level in the presence of 
progressive malignancy has been recognized since at least 1950 (Mider et al., 1950). 
Hypoalbuminemia as a prognostic aid in various common types of cancer, albumin 
concentration is one of the most accurate indicators of progression in multiple 
myeloma (Blade et al., 1989; Chen and Magalhaes, 1990), where patients with stage-
Ill myeloma had albumin <38g/L, and a level below 30 g/L identified unequivocally 
advanced disease malignant melanoma (Sirott et al., 1993); in several clinical studies 
it was the most significant single marker. 
Thought to be tied to anorexia, the low albumin level cannot be raised toward 
normal even by parenteral nutrition strenuous enough to cause a gain in total body 
weight (Gray and Meguid, 1990). The primary cause of hypoalbuminemia is a 
specific inhibition of albumin gene transcription by the tumor necrosis factor, TNFa, 
reducing the level of albumin mRNA as much as 90%. Injection of TNFa also has the 
effect of increasing transendothelial passes of albumin (Hennig et al., 1988), which 
acts to lower its concentration in the circulation. 
Another factor is the increased albumin degradation observed with malignancy 
(Rossing, 1968). Tumors utilize albumin and other plasma proteins for their nutrition 
at a greater rate than do normal tissues, the uptake of labeled albumin was three fold 
higher in sarcomas than in normal mouse (Andersson et al, 1991). The increased 
breakdown is largely due to host factors and is not caused by abnormalities in the 
albumin molecule, which appeared normal in these mice (Anderson et al, 1990). 
When hepatocytes became malignant (liver cancer) there is a graded loss of 
albumin-synthesizing ability depending on the degree of dedifferentiation of the 
tumor. Four subclones of the rat hepatoma cell line FUS-5, for distance, produce 
albumin at the rate of 0, 0.3, 1.7, and 16 i^g/mg cell protein / 48h (Wolf er al, 1983). 
Metastases of primary hepatomas as blood-borne hepatic tumor cells are now readily 
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detected through PCR analysis of the blood cellular faction for albumin mRNA 
(Hilliaire era/., 1994). 
Paraprotein released by plasma cell tumors and lymphomas can display unsual 
properties. HSA-monoclonal IgG complex in a patient with Von Willenbrands disease 
harbored low-affinity binding sites for bilrubin (Gulian et ai, 1993). A monoclonal 
IgM protein binds bromcresol green and interferes with the commonly used BCG 
assay (Reed, 1987). In five reported cases monoclonal proteins produced by 
myelomas anti-HSA immune specificity, presumably a random occurrence. Two were 
of IgA and three of IgG class, detectable as circulating antigen-antibody complexes; 
one of the IgA complexes were attached to HSA by S-S bonds (Eilat et al., 1981). 
Two of the HSA-IgG complexes acted as cryoglobulin, precipitating in the cold, and 
could readily be crystallized (Jentoft et al., 1987). They contained HSA/lgG-X, in the 
ratio 2:1, and sedimented at 12.5 S (Peters, 1996). 
Diabetes 
Diabetes mellitus (DM) comprises a group of common metabolic disorders 
that share the phenotype of hyperglycemia. Several distinct types of DM exist and are 
caused by a complex interaction of genetics, environmental factors, and Hfe-style 
choices. Depending on the etiology of the DM, factor contributing to hyperglycemia 
may include reduced insulin secretion, decreased glucose utilization, and increased 
glucose production (Kasper et al., 2005). 
DM is a state of chronic hyperglycemia associated with a high risk of 
atherosclerosis, renal, nervous system, ocular damage that leads to increase 
myocardial infrtiction, stroke and limb amputation (Zimmet et al., 2001, Quinn, 
2001). A wide spectrum of pathogenic processes is involved in the development of 
DM which may range from autoimmune destruction of beta cells to the development 
of insulin resistance. The major risk factors of DM are age, obesity, lack of exercise, 
along with a strong genetic predisposition. A strong HLA association with some 
forms of the disease along with some specific antibodies has also been identified. The 
pathogenic link between hyperglycemia and the complications of diabetes is unknown 
(Zimmet e/a/., 2001). 
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Classification 
DM is classified on the basis of the pathogenic process that leads to 
hyperglycemia, as opposed to earlier criteria such as age of onset or type of therapy. 
The two broad categories of DM are designated type 1 and type 2. 
Type 1 has been further subdivided into 1A and IB. Type lA DM results from 
autoimmune beta cell destruction, which leads to insulin deficiency. Individuals with 
type IB DM lack immunologic markers indicative of an autoimmune destructive 
process of the beta cells. However, they develop insulin deficiency by unknown 
mechanisms. 
Type 2 DM is a heterogeneous group of disorders characterized by variable 
degree of insulin resistance, impaired insulin secretion, and increased glucose 
production. Distinct genetic and metabolic defects in insulin action and/or secretion 
give rise to the common phenotype of hyperglycemia in type 2 DM (Kasper el al., 
2005). 
However, the American Diabetes Association, 2004 gave other etiologies for 
DM include specific genetic defects in insulin secretion or action, metabolic 
abnormalities that impair insulin secretion, mitochondrial abnormalities, and a host of 
conditions that impair glucose tolerance. Maturity onset diabetes of the young 
(MODY) is a subtype of DM characterized by autosomal dominant inheritance, early 
onset of hyperglycemia, and impairment in insulin secretion. Mutations in the insulin 
receptor cause a group or rare disorders characterized by severe insulin resistance. 
DM can result from pancreatic exocrine disease when the majority of 
pancreatic inslet (>80%) are destroyed. Hormones that antagonize the action of 
insulin can lead to DM. Thus, DM is often a feature of endocrinopathies, such as 
acromegaly and Cushing's disease. Viral infections have been implicated in 
pancreatic islet destruction, but are an extremely rare cause of DM. Congential rubella 
greatly increases the risk for DM, however, most of these individuals also have 
immunologic markers indicative of autoimmune beta cell destruction. Another form 
of DM is gestational diabetes mellitus (GDM), GDM occurs as insulin resistance 
related to the metabolic changes of late pregnancy increases insulin requirements and 
may lead to impaired glucose tolerance. GDM occurs in approximately 4% of 
pregnancies in the United States; most women revert to normal glucose tolerance 
post-partum but have a substantial risk (30-60%) of developing DM later in life 
(Adapted from American Diabetes Association, 2004). 
Oxygen Free Radical in Diabetes 
Oxidative stress plays a central role in the onset of diabetes mellitus as well as 
in diabetes associated complications (Phillips, 2004). Various studies have shown that 
DM is associated with increased formation of free radicals and decrease in antioxidant 
potential. This leads to oxidative damage of cell components such as proteins, lipids 
and nucleic acid. In both type 1 and type 2 DM there is increased oxidative stress 
(Nazirogjlu and Butterworth, 2005). 
Hyperglycemia increases the production of reactive oxygen species (ROS) and 
decreases their scavenging by various mechanisms. Such an increase of ROS may 
disturb or modify various cellular functions and alter gene expression due to oxidative 
stress. High glucose induced mitochondrial overproduction of ROS (Nishikawa et al., 
2000) and abnormal activation of NAD (P) H oxidase (Kim, et al, 2002; Inoguchi et 
al, 2003) are thought to be the major sources of ROS associated with hyperglycemia, 
while sustained hyperglycemia may also decrease radical scavenging by manganese 
superoxide dismutase (Yan and Harding,. 1997) and the glutathione redox cycle 
(Kashiwagi et ai, 1996). Thus, chronic oxidative stress is thought to be major cause 
of diabetic complications, and clinical evolution of the accumulation of oxidative 
stress induced by sustained enhancement of ROS production could be useful to assess 
the risk of diabetes complications. However, the current clinical markers of ROS in 
diabetes, such as urinary 8-OH-2'-deoxyguanosine (Dandona et al., 1996), urinary 8-
iso PGE 2a (Patrona and FitzGerald, 1997), plasma lipid peroxide (Meagher et al., 
2001) and the most important marker oxidized form of HSA (HNA) (Suzuki et al., 
1992; Oettl et al., 2005), all reflect short-term ROS formation and not cumulative 
oxidative stress. 
Increased oxidative stress in diabetic patients may lead to protein oxidation 
(Telci et al., 2000). The conversion of protein to protein carbonyl (PCO) derivatives 
occurs via direct oxidation by ROS, with the eventual formation of oxidized amino 
acids (Carrad et al, 2002; Stadtman and Levine, 2000). 
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Oxidative protein damage cannot be repaired, except for the oxidation of 
methionine and cytseine (Stadtman, 2002). These oxidations cause irreversible 
modifications in protein. The structure and activity of oxidized proteins change 
profoundly in comparison with their native forms. Oxidative modification of proteins 
in vivo may affect a variety of cellular functions. The best marker for intracellular 
oxidative stress-dependent cellular damage is the PCO content. The unique advantage 
of the carbonyl measurement as a good marker of oxidative stress is the fact that it 
covers a much wider range of oxidative damage than other markers do (Cakatay et al., 
2003; Carrard ei al, 2002; Evans et al, 1999; Reznick and Packer, 1994). The other 
markers, such as nitrotyrosine, hydroxylation of aromatic, and hydrophobic amino 
acids, are at a very low level in comparison with the carbonyl content. 
Diabetes: The Serum Albumin Connection 
In diabetes the circulating albumin level is depressed. A 30-40% fall in the 
rate of albumin synthesis in uncontrolled diabetic patients as well as in perfused livers 
of diabetic rates can be restored by in vivo insulin; one basis is a marked decline in 
transcription of albumin mRNA. Albumin degradation and relative extravascular 
distribution volume are likewise decreased about 35%o in diabetic rats (Murtiashaw et 
al., 1983). 
Other features of diabetes are the effects of nonenzymatic glycation of 
circulating albumin; two laboratories almost concurrently reported nonenzymatic 
glycation of serum albumin (Dolhofer and Wieland, 1979; Guthrow et al., 1979). 
Antibodies to the in vivo form of glycoalbumin have been sought but not detected 
(Gregor et al., 1986). If albumin is glycated in the presence of reducing agent such as 
borohydride, so that the glucose becames a glucitol-lysine adduct, antibodies to this 
group are claimed to be widely present in both normal and diabetic subjects, as both 
IgG and IgM isotypes (Nakayama et al., 1985; Mangili et al., 1988). 
One of the feature of diabetes is the detection of an increase in albumin 
urinary excretion as a harbinger of incipient kidney damage (Keen and Chiouverakis, 
1963; Hawthorene, 1989). Speculation that albumin from cow's milk may be an 
etiological factor in juvenile-onset diabetes as serum albumin is only present in cow's 
milk at 0.4g/L, it appears to be antigenic in man as a food allergen. Serum albumin 
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from bovine is found in circulating immune complexes in patients with IgA 
nephropathy (Yap et al, 1987) or recurrent angioedema (Lefvert, 1993), and as an 
IgE complex in eosinophilic gastroenteritis (Verdaguer et al., 1993). A segment of 
BSA, residues 126-144 in the ascending arm of loop 3, with the sequence 
FKADEKKFWGKYLYEIARR, termed "ABBOS" by a research group at Toronto 
(Martin et ah, 1991), was found by them to show homology with residues « 56-76 of 
a cell-surface protein, p69, of the pancreatic istel P-cell, and has been synthesized by 
them as a test antigen. They find circulating humoral antibodies against this peptide in 
children newly diagnosed with IDDM; these antibodies disappear along with 
disappearance of (3-ceIl disfunction after a few years. 
Their hypothesis (Karjalainen et al, 1992) is that this peptide reaches the 
immune system of infant receiving cow's milk during the first 3 months of life, when 
the gut allows large fragments of protein to be absorbed. In the case of susceptible 
infants, the peptide shares an epitope with the ^-cell p69 protein, and evokes an 
immune response to this protein that persists even after the gut matures. Laters, 
unrelated infections or other acute-phase reactions induce the expression of p69 on the 
surface of (3-ceII, and the immune system attacks and destroys these cells; insulin 
production is simultaneously lost and IDDM results. 
Although this is an attractive scheme that explain many phenomena about the 
onset of a severe disease. Atkinson et al. (1993) note that cellular, not humoral, 
immune mechanisms are considered to cause IDDM. They could not demonstrate a 
proliferative response of mononuclear cells to bovine serum albumin or to the above 
peptide. Their results question the relevance of BSA or its fragments in the 
pathogenesis of the disease, and favor the role of autoimmunity. 
Anti-HSA antibodies have been observed in diabetes (Eilat et al., 1981), a five 
fold greater occurrence of anti-HSA antibodies in diabetic patients than in nondiabetic 
person (Gregor et al, 1986). Sera from patients with familial dysautonomia contain 
high levels of anti-HSA antibodies, which correlate with levels of anti-BSA 
antibodies and decline exponentially after infancy (Chapman et al, 1993), suggesting 
that they contribute to the pathological changes in this condition. 
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Alteration of redox state of HSA in patients with diabetes mellitus may be the 
important parameter for the pathogenesis of the disease, as oxidixed form of HSA 
increased in diabetic patients (Suzuki et al., 1992; Oettl et al., 2005). 
Objective of the Present Study 
Free radicals are produced in living cells by normal metabolism and by 
exogenous sources such as carcinogenic compounds and ionizing radiations. Of these 
radicals, the highly reactive hydroxyl radical (OH) caused damage to protein and 
nucleic acids also termed as oxidative damage. Reactive oxygen species (ROS) have 
been implicated in the etiology of many human diseases including SLE, cancer and 
diabetes. 
In the present study, commercially available human serum albumin (HSA) 
was modified with hydroxyl radical, generated by UV irradiation hydrogen peroxide. 
Native and OH modified HSA were characterized by UV spectroscopy, far and near 
UV regions of circular dichromism, fluorescence spectroscopy, polyacrylamide gel 
electrophorosis, thermal denaturation, HPLC anion exchange chromatography and 
carbonyl estimation. Antigenicity of native and ROS-modified HSA was probed by 
inducing polyclonal antibodies in experimental animals. The repertoire of specificities 
of induced antibodies was evaluated by their binding to various blood proteins, 
nucleic acids and their ROS-modified conformers. In order to assess the possible role 
of ROS-modified epitopes in the aetiology of autoimmune diseases, sera from various 
SLE and type 1 diabetes patients were studied for their recognition of native and 
ROS-modified HSA. ROS-modified HSA was also used as a probe to detect oxidative 
damage to HSA in various types of cancers. 
'EwerimentaC 
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MATERIALS 
Human serum albumin (HSA) essentially fatty acid free, anti-human/anti-
rabbit IgG-alkaline phosphatase conjugate, p-nitrophenyl phosphate, Tween-20, SDS-
molecular weight protein markers, calf thymus DNA, nuclease S1, ethidium bromide, 
Coomassie Brilliant Blue G-250 and R-250, sodium dodecyl sulphate, Millipore filter, 
Freund's complete and incomplete adjuvants, agarose, bovine serum albumin, 
ampicilin and mannitol were purchased from Sigma Chemical Company, U.S.A. 
Protein-A Sepharose CL-4B was purchased from Genei, India. Sephacryl S-200 HR, 
Ficoll 400 and xylene cyanole FF were purchased from Pharmacia Fine Chemicals, 
Sweden. Folin-Ciocalteau reagent and Blue Dextran 2000 were purchased from 
Centre for Biochemical Technology, New Delhi, India. Absolute ethanol was 
obtained from BDH Laboratory Supplies, England. Polystyrene microtitre flat bottom 
ELISA plates and modules were purchased from NUNC, Denmark. Qiagen plasmid 
mega kit, acrylamide, ammonium persulphate, bisacrylamide, N,N,N,N-
tertramethylethylenediamine (TEMED) were from Bio-Rad Laboraties U.S.A. EDTA 
(disodium salt), hydrogen peroxide, sucrose, chloroform, isoamylalcohol, methanol, 
glacial acetic acid were from Qualigens, India. All other reagents/chemicals were of 
the highest analytical grade available. 
Equipments 
Shimadzu UV-240 spectrophotometer equipped with thermo-programmer and 
controller unit, ELISA micorplate reader, Elico pH meter model LI-120, ultraviolet 
lamp (Vilber Lourmat, France), agarose gel electrophoresis assembly (GNA-100), 
Beckman ultracentrifuge, Avanti 30 table top high speed refrigerated centrifuge 
(Beckman, U.S.A.), polyacrylamide gel electrophoresis assembly (Bio-Rad, U.S.A.), 
Hitachi F-200 spectrofluorophotometer (Japan), Amershan Biosciences akta purifier 
column resource Q anion exchanger, and Jasco spectropolarimeter (model J-720) 
were the major equipments used in this study. 
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Collection of Sera and Blood Samples 
Normal human sera (n = 22) were obtained from healthy subjects. SLE serum 
samples were obtained from outdoor and indoor patients of the Department of 
Medicine, All India Institute of Medical Sciences, New Delhi. SLE sera from 54 
female of age ranging from 35-75 years (mean 48.2 ± 9.5) were studied. All SLE sera 
showing high titre anti-DNA antibodies that satisfied the American College of 
Rheumatology (ACR) criteria for the diagnosis of SLE (Arnett et al., 1988) were used 
in this study. 
Sera of cancer patients proven with histopathological diagnosis were obtained 
from J.N. Medical College Hospital A.M.U., Aligarh and from All India Institute of 
Medical Sciences, New Delhi. 
Blood was collected from voluntary donors with history of type 1 diabetes 
mellitus (n = 31, male = 19, female = 12) under treatment in J.N. Medical College 
Hospital A.M.U., Aligarh. The control blood samples (n = 10, male = 6, female == 4) 
were collected from normal healthy subjects. The post prandial blood sugar level for 
diabetic patients was > 200 mg/dl while it was < 140 mg/dl for healthy subjects 
(without family history of diabetes). The gycated hemoglobin (HbAlC) was 
considered to be normal at < 6% and that of diabetes patients of poor glycemic control 
was > 6%. 
All sera were decomplemented by heating at 56°C for 30 min and stored in 
aliquots at -20°C with sodium azide as preservative. 
Protein Estimation 
Protein was estimated by the methods of Lowry et al. (1951), Bradford (1976) 
or HSA concentration was measured spectrophotometrically using E'°''°]cm of 5.30 at 
280 nm (Wallevik, 1973). 
Protein Estimation by Folin's-Phenol Reagent 
The protein estimation by this method utilizes alkali (to keep the pH high), 
9+ 9-1-
Cu ions (to chelate proteins) and tartarate (to keep the Cu ions in solution at high 
pH). 
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(a) Folin-Ciocalteau Reagent 
The reagent was purchased from Centre for Biochemical Technology, New 
Delhi and diluted 1:4 with distilled water before use. 
(b) Alkaline Copper Reagent 
The components of alkali copper reagent were prepared as follows: 
(i) 2 percent sodium carbonate in 100 mM sodium hydroxide 
(ii) 0.5 percent copper sulphate in 1.0 percent sodium potassium tartarate. 
The working reagent was prepared fresh before use by mixing components (i) 
and (ii) in the ratio of 50:1. 
(c) Procedure 
To 1.0 ml of protein sample was added 5.0 ml of alkaline copper reagent and 
incubated for 10 min at room temperature. One ml of working Folin-Ciocalteau 
reagent was added and the tubes were read at 660 nm after 30 min. The concentration 
of protein in unknown sample was determined from a standard plot of bovine serum 
albumin. 
Protein Estimation by Dye-Binding Method 
This assay is based on color change observed when Coomassie Brilliant Blue 
G-250, an acidic dye, binds hydrophobically to protein having positively charged 
groups (Bradford, 1976). In the environment of these positively charged groups, 
protonation is suppressed and a blue color is observed (A,max =595 nm). 
(a) Dye Preparation 
One hundred mg Coomassie Brilliant Blue G-250 was dissolved in 50 ml of 
95% ethanol and 100 ml of 85% (v/v) orthophosphoric acid was added. The resulting 
solution was diluted to a final volume of 1 liter and filtered through a Whatman No.l 
filter paper to remove undissolved particles. 
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(b) Protein Assay 
To 1ml solufions, containing 10-100 \xg protein, 5 ml of dye solution was 
added and the contents were mixed by vortexing. The absorbance was read at 595 nm 
after 5 min, against a reagent blank. 
Determination of DNA Concentration 
DNA concentration was estimated colorimetrically by the method of Burton 
(1956) using diphenylamine reagent. 
(a) Crystallization of Diphenylamine 
Diphenylamine (2 gm) was dissolved in 200 ml boiling hexane. After adding 
0.5 gm of activated charcoal, the hot mixture was filtered through Whatman No. 1 
filter paper and the filtrate was kept overnight at 4 °C and dried at room temperature 
before use. 
(b) Preparation of Diphenylamine Reagent 
750 mg of recrystallized diphenylamine was mixed with 50 ml of glacial 
acetic acid and 0.75 ml concentrated sulphuric acid. The reagent was prepared fresh 
before use. 
(c) Procedure 
One ml of DNA sample was mixed with 1.0 ml of IN perchloric acid and 
incubated at 70 °C for 15 min. 100 |il of 5.43 mM acetaldehyde was added followed 
by 2 ml of freshly prepared diphenylamine reagent. The contents were mixed and 
incubated at room temperature for 16-20 hrs. Absorbance was read at 600 nm and the 
concentration of DNA in unknown samples was determined from a standard plot of 
calf thymus DNA purified free of RNA and proteins. 
Purification of Calf Thymus DNA 
Commercially available calf thymus DNA was purified free of proteins and 
single stranded regions as described by Ali et al. (1985). DNA (2 mg/ml) was 
dissolved in 0.1 X SSC buffer (15 mM sodium citrate and 150 mM sodium chloride, 
pH 7.3) and extracted with an equal volume of chloroform isoamylalcohol (24:1) in a 
stoppered container for 1 hr. The aqueous layer containing DNA was separated from 
the organic layer and re-extracted with chloroform-isoamyl alcohol. The DNA was 
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precipitated with two volume of cold absolute ethanol and collected on a glass rod. 
After drying in air, the DNA was dissolved in acetate buffer (30 mM sodium acetate 
containing 30 mM zinc chloride, pH 5.0) and treated with nuclease SI (150 units/mg 
DNA) at 37 °C for 30 min to remove single stranded regions. The reaction was 
stopped by adding one-tenth volume of 200 mM EDTA, pH 8.0. The nuclease SI 
treated DNA was extracted twice with chloroform: isoamyl alcohol and finally 
precipitated with two volumes of cold ethanol. The precipitate was dissolved in 
phosphate-buffered saline (PBS) (10 mM sodium phosphate containing 150 mM 
sodium chloride), pH 7.4. 
Polyacrylamide Gel Electrophoresis 
PAGE was performed as described by Laemmli (1970). 
(i) Acrylamide-Bisacrylamide (30:0.8) 
A stock solution was prepared by dissolving 30 gm of acrylamide and 0.8 gm 
bis-acrylamide in distilled water to a final volume of 100 ml. 
(ii) Resolving Gel Buffer 
A stock solution was prepared by dissolving 18.2 gm Tris base in 48.0 ml of 
IN HCl. The contents were mixed, pH adjusted to 8.8 and the final volume brought to 
100 ml with distilled water. 
(iii) Electrode Buffer 
3.03 gm Tris, 14.4 gm glycine and/or 1.0 gm SDS were dissolved in distilled 
water, pH adjusted to 8.3 and final volume made up to one litre. 
(iv) Procedure 
Glass plates, separated by 1.5 mm thick spacer were sealed with 1% agarose. 
The 7.5% resolving gel mixture was prepared by mixing the components in the 
appropriate volume and poured into the space between the glass plates leaving 
sufficient space at the top for the 2.5%) stacking gel. After the polymerization of 
separating gel, 2.5% stacking gel mixture was poured and allowed to solidify. Protein 
samples containing 10% (w/v) glycerol, or 2% (w/v) SDS, or 5% (v/v) 
merceptoethanol and 0.002% bromophenol blue were applied. The electrophoresis 
was carried out at 50V to 80V for 3 to 8 h and protein were visualized using 
coomassie brilliant blue R-250 or by silver nitrate staining. 
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Recipe for Native PAGE 
Solution 7.5%) Resolving gel 2.5% Stacking gel 
Acrylamide-bisacrylamide 
Resolving gel buffer 
Distilled water 
1.5% Ammonium persulphate 
TEMED 
7.5 ml 
3.75 ml 
16.95 ml 
1.5 ml 
15 ML 
1.25 ml 
2.5 ml 
5.65 ml 
0.5 ml 
0.75 |JL 
Staining Procedures 
Two staining methods were employed 
(a) Coomassie Brilliant Blue Staining 
Protein bands were detected by staining with 0.\% Coomassie Brilliant Blue 
R-250 in 40%) isopropanol and 10% glacial acetic acid. Destaining was carried out in 
a mixture of 10%o glacial acetic acid and 20% methanol. 
(b) Silver Nitrate Staining 
The procedure described by Merril et al. (1982) was followed with some 
modifications. After electrophoresis, the protein bands were fixed by rapidly 
immersing in a mixture of 40 % methanol and 13.5 % formaldehyde for 15 min with 
instant shaking. The gel was washed with distilled water twice, transferred to 0.02% 
Na2S203 solution for 2 min. The gel was again rinsed twice with distilled water. 
This was followed by incubation with 0.1 % AgNOs solution for 20 min. The gel was 
rinsed with distilled water briefly, immersed in developer solution (3% sodium 
carbonate solution containing 0.5%) formaldehyde and 0.02% Na2S203) for 15 min or 
until properly stained. The reaction was stopped by transferring the gel to stopper 
solution (25% isopropanol solution containing 10% acetic acid glacial) for 5 min. The 
gel was washed twice with distilled water and finally stored in distilled water. 
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Agarose Gel Electrophoresis 
Agarose (0.8% or 1%) in TAE buffer (40 mM Tris-acetate, pH 8.0 containing 
2 mM EDTA) was dissolved by heating. The solution was cooled to about 50 °C and 
then poured into gel tray and allowed to solidify at room temperature. DNA samples 
were mixed with one-tenth volume of sample buffer (0.125% bromophenol blue, 30% 
Ficoll 400, 500 mM EDTA in lOX electrophoresis buffer). The samples were loaded 
in the wells and electrophoresed was carried out for 1.5 - 2.5 h at 30 mA in TAE (40 
mM Tris-acetate 9 mM EDTA, pH 8.0) buffer The gels were stained with ethidium 
bromide (0.5 ng/ml), viewed by illumination under UV light. 
Modification of Human Serum Albumin 
HSA was modified in PBS (10 mM sodium phosphate buffer containing 150 
mM NaCl, pH 7.4) by a published procedure with slight modifications (Waris and 
Alam, 1998; Mansoor et al, 2005). An aqueous solution of native HSA (3.75 ^M) 
was modified by hydroxyl radical, generated by the UV irradiation (30 minutes) of 
hydrogen peroxide (31 mM) at 254 nm. Excess hydrogen peroxide was removed by 
extensive dialysis against PBS. 
Spectroscopic Analysis 
The ultraviolet spectra of native and ROS-HSA samples were recorded in the 
wavelength range of 200-400 nm on a Shimadzu UV-240 spectrophotometer. The 
modifications incurred on native HSA were also analyzed by UV-difference 
spectroscopy. 
Circular Dichroism Measurements 
CD. measurements were carried out with Jasco spectropolarimeter, model J-
720 equipped v i^th a microcomputer. The instrument was calibrated with D-10-
camphorsulfonic acid. The CD measurements were made at 25°C with a 
thermostatically controlled cell holder attached to Neslab's RTE 110 water bath with 
an temperature accuracy of ± O.TC. Spectra were taken with a scan speed of 20 
nm/min at a response time of 1 s. Each spectrum was the average of four scans. Far-
UV CD spectra were taken at protein concentration of 3.0 \xM with a cell of 1 mm 
42 
path length and the near-UV CD spectra were taken at 20.0 |iM protein concentration 
with a 10 mm path length. The MRE (mean residue ellipicity) was expressed in 
deg.cm^.mol"', MRE = CD / (lOxn^lxCp) where CD in milli-degree, n is the number 
of amino acid residues (585), 1 is the path length of the cell, and Cp is the mole 
fraction. Helical content was calculated from the MRE values at 222 nm using the 
following equation (Chen et al, 1972). 
% Alpha helix == (MRE222 nm -2340/30300) x 100 
Fluorescence Measurements 
Fluorescence measurements were performed on spectrofluorimeter (Shimadzu 
RF-1501, Japan). The fluorescence spectra were measured at 25 ± O.TC with a cell of 
1 cm path length. The excitation and emission slits were set at 5 and 10 nm, 
respectively. Intrinsic fluorescence was measured by exciting the protein solution at 
280 or 295 nm and emission spectra were recorded in the range of 300-400 nm. Loss 
of fluorescence intensity (F.I.) was calculated using the following equation 
% L o s s o f F.I . = (F . I . native HSA - F.I . modified HSA)/ F . I . native HSA) ^ 100 
SDS-PAGE Under Reducing and Non-Reducing Conditions 
Native and ROS modified HSA were characterized by SDS-PAGE under 
reducing and non-reducing conditions, using 12% and 7.5% (w/v) acrylamide gels, 
respectively. For reducing SDS-PAGE, samples were heated for 5 minutes at 95°C in 
a samples buffer that contained 50 mM Tris-HCl, pH 6.3, 2% (w/v) SDS, 10% (w/v) 
glycerol, 5% (v/v) mercaptoethanol, 0.002% (w/v) bromophenol blue. For non-
reducing SDS-PAGE, samples were not heated and samples buffer contained all 
above chemicals except mercaptoethanol. Gels were electrophoresed at 50 V for 3-4 h 
and proteins were visualized using silver nitrate staining and coomassie brilliant blues 
R-250. 
Absorption-Temperature Scan 
Thermal denaturation profile of protein was performed on a Shimadzu UV-
240 spectrophotometer equipped with a temperature programmer and controller 
assembly (Hasan and Ali, 1990). Protein samples were in PBS, pH 7.4 and 
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absorbance was recorded at a fixed wavelength of 280 nm. Percent denaturation was 
calculated using the equation: 
A T - A30 
Percent denaturation = X 100 
Amax A30 
Where, AT = Absorbance at a temperature T °C. 
Amax = Final maximum absorbance on the completion of 
denaturation (95 °C). 
A30 = Initial absorbance at 30 °C. 
HPLC Analysis 
HPLC analysis was carried out with Amershan Biosciences akta purifier 
column resource Q anion exchanger, equipped with a microcomputer. Native or 
modified HSA at a concentration of 5.11 x 10""^  M in 0.01 M Tris, pH 7.4 was allowed 
to bind the exchanger and elution was done by 0 to 0.5 M NaCl gradient. 
Assay of Carbonyl Formation 
Carbonyls contents of native and ROS-modified HSA were analyzed 
according to Levine et al. (1990) with slight modifications. The reaction mixture 
containing 15 (iM native HSA or ROS-HSA, 0.5 ml of 10 mM 2, 4-
dinitrophenylhydrazine (DNPH) / 2.5 M HCl was added and thoroughly mixed. After 
addition of 250 fiM TCA (20%) and centrifugation, the pellet was collected and 
washed three times with 1 ml ethanol : ethylacetate (1:1) mixture. The pellet was then 
dissolved in 1 ml of 6 M guanidine solution and incubated at 30°C for 15 min. After 
centrifugation, the supernatant was collected and carbonyl contents were estimated 
from the absorbance at 370 nm using a molar absorption coefficient of 22,000 M"'cm 
. Samples were spectrophotometrically analyzed against a blank of 1 ml of guanidine 
solution (6 M). Protein concentration was determined in the samples by the method of 
Lowry et al. (1951). Carbonyl contents were expressed as nmol/ mg protein. Similar 
procedure was used for the estimation of protein carbonyl contents in patient serum 
protein and in isolated HSA from patients of SLE, cancer and diabetes. 
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Immunization Schedule 
Native and ROS-modified HSA (100 |^ g) were emulsified with an equal 
volume of complete Freund's adjuvant and injected intramuscularly in female rabbits. 
Subsequent injections were given in incomplete Freund's adjuvant. Each animal 
received a total of 600 i^ g of antigen in the course of 6 injections. Blood was collected 
from marginal vein of the ear. Serum was separated and decomplemented by heating 
at 56 °C for 30 min. Pre-immune serum was collected prior to immunization. The sera 
were stored in small aliquots at -20 °C with 0.1% sodium azide as preservative. 
Isolation of Human Serum Albumin 
Human serum albumin (HSA) was prepared according to the method 
described earlier (Tayyab and Qasim., 1990). Briefly plasma as obtained from normal 
human blood and patients of SLE, bladder cancer and diabetes was brought to 2 . 2 6 ^ 
in ammonium sulphate by adding requisite volume of 4M ammonium sulphate 
solution, pH 7.0. The mixture was kept for 12 hours at room temperature and then 
carefully diluted with water and with frequent addition of 0.5 N H2SO4 such that the 
final concentration of ammonium sulphate was reduced to 1.9 M and the pH to 4.2. 
After incubating it for 12 hours at room temperature, the precipitate was collected by 
centrifugation at 3000g for 30 mins. It was washed 3 times with 2.2 M ammonium 
sulphate solution, pH 4.2 and then dissolved in 0.06 M sodium phosphate buffer, pH 
7.4 containing 0.08 M NaCl. The protein preparation thus obtained was serum 
albumin, extensively dialyzed against 6 liters of the 0.06 M sodium phosphate buffer 
pH 7.4 and stored at 4°C. 
Gel Chromatography 
Column of Sephacryl S-200 HR (40x2.0 cm) was packed according to the 
published procedure (Tayyab et al., 1991) and equilibrated with 0.06 M sodium 
phosphate buffer, pH 7.0. The void volume of the column was determined by passing 
a band of blue dextran (10 mg/2ml) and was found to be 40 ml. Nearly 10 mg of each 
dialyzed samples in 1 ml of 0.06 M sodium phosphate buffer, pH 7.0 were loaded on 
to the column and eluted with the same buffer at a flow rate of 15-20 ml/h in 3-5 ml 
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fractions. Protein in each fraction was monitored by the method of Lowry et al. 
(1951). 
Isolation of Plasmid DNA 
Plasmid DNA was isolated from E. coli strain DH5 a "KS" by using Qiagen 
plasmid Mega kit (QIAGEN GmbH-Germany or USA). 
(a) Material Used 
Cell Strains and Media - Escherichia coli strain DH5 a "KS" was used 
throughout the study. Luria Broth was used and ampicillin was added at a 
concentration of 100 \iglm\. RNase A solution was added to buffer PI to give a final 
concentration of 100 |J.g/ml supplied in the kit. 
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(b) Composition of buffers in the kit 
Buffer Composition Storage 
Buffer PI (resuspension 
buffer) 
50 mM Tris-HCl, pH 8.0 
lOmMEDTA; 
100)ig/mlRNaseA 
4 °C, after addition of 
RNase A 
Buffer P2 (lysis buffer) 200 mM NaOH, 1 % SDS room temp. 
Buffer P3 (neutralization 3.0 M potassium acetate, 
buffer) pH 5.5 
Buffer FWB (QIAfilter 
wash buffer) 
750 mM NaCl; 
50 mM MOPS, pH 7.0 
15% isopropanol 
Buffer QBT (equilibration 750 mM NaCl; 
buffer) 50 mM MOPS, pH 7.0 
15% isopropanol; 
0.15% Triton X-100 
room temp, or 4 °C 
room temp. 
room temp. 
Buffer QC (wash buffer) 1.0 M NaCl; 
50 mM MOPS, pH 7.0; 
15%) isopropanol 
Buffer QF (elution buffer) 1.25 M NaCl; 
50 mM Tris-HCl, pH 8.5 
15%) isopropanol 
Buffer QN (elution buffer) 1.6 M NaCl; 
50 mM MOPS, pH 7.0 
15%) isopropanol 
TE 10 mM Tris-HCl, pH 8.0 
1 mM EDTA 
room temp. 
room temp. 
room temp. 
room temp. 
STE 100 mM NaCl; 
10 mM Tris-HCl, pH 8.0; 
1 mM EDTA 
room temp. 
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Preparation of Plasmid DNA 
Plasmid containing E. coli cells were grown in 10 ml L-broth containing 100 
Hg/ml ampicillin. After ~8 hrs. incubation at 37 °C, with vigorous shaking (-300 rpm) 
the culture was transferred to 500 ml L-broth containing 100 |ig/ml ampicillin and 
further incubated for 12-16 hrs. at 37 °C. Cells were harvested by centrifugation at 
6000 X g (6000 rpm) for 15 min. at 4 °C. The supernatant was discarded off The open 
centrifuge tube was left in an inverted position to allow all of the supernatant to drain 
away. The bacterial cell pellet was resuspended in 50 ml of buffer PI containing 
RNase A. The cells were resuspended completely by vortexing or pipetting up and 
down until no cell clumps remain. Added 50 ml of buffer P2, mixed gently but 
thoroughly by inverting 4-6 times, and incubated at room temperature for 5 min. Then 
added 50 ml of chilled buffer P3 mixed immediately but gently by inverting 4-6 times 
and incubated on ice for 30 min. Mixed the sample several times during the 
incubation on ice. The sample was centrifuge at >20,000 x g for 30 min. at 4 °C. Re-
centrifuged the supernatant again at >20,000 x g for 15 min. at 4 °C. Removed 
promptly supernatant containing plasmid DNA. Equilibrated a QIAGEN-tip 2500 by 
applying 35 ml buffer QBT and allowed the column to empty by gravity flow. The 
supernatant was applied to the QIAGEN-tip and allowed it to enter the resin by 
gravity flow. Washed the Qiagen-tip with 2 x 100 ml buffer QC. DNA was eluted 
with 35 ml buffer QF. Precipitated DNA by adding 24.5 ml (0.7 volumes) room-
temperature isopropanol to the eluted DNA. Mixed and centrifuged immediately at 
>15,000 X g for 30 min at 4 °C. The supernatant was carefully decanted off DNA 
pellet was washed with 7 ml of room-temperature 70% ethanol and centrifuged again 
at > 15,000 X g for 10 min. Carefully decanted the supernatant without disturbing the 
pellet. Air-dried the pellet for 10-20 min and redissolved the DNA in a suitable 
volume of TE, pH 8.0. DNA concentration was determined by UV absorbance and 
subjected to agarose gel electrophoresis. 
Isolation of IgG by Protein A-Sepharose CL-4B Affinity Column 
Serum IgG was isolated by affinity chromatography on Protein A-Sepharose 
CL-4B column. Serum (0.3 ml) diluted with equal volume of PBS, pH 7.4 was 
applied to column (12 mm X 45 mm) equilibrated with the same buffer. The wash 
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through was recycled 2-3 times. Unbound IgG was removed by extensive washing 
with PBS, pH 7.4. The bound IgG was eluted with 0.58%o acetic acid in 0.85%) sodium 
chloride (Coding, 1976) and neutralized with 1 ml of IM Tris-HCl, pH 8.5. Three ml 
fractions were collected and read at 251 and 278 nm. IgG concentration was 
determined considering 1.40 OD280 - 10 mg/ml. The isolated IgG was then dialyzed 
against PBS, pH 7.4 and stored at -20°C with 0.1 %) sodium azide. 
Immunological Detected of Antibodies 
Sera were tested for antibodies by enzyme linked immunosorbent assay, 
immunoduffsion, immunoprecipitin titration and gel retardation assay. 
(a) Enzyme Linked Immunosorbent Assay 
The following reagents were prepared in distilled water and used in enzyme 
immunoassay. 
(1) Buffers and Reagents 
Tris Buffered Saline (TBS) 
10 mM Tris, 150 mM NaCl, pH 7.4 
Tris Buffered Saline-Tween 20 (TBS-T) 
20 mM Tris, 144 mM NaCI, 2.68 mM KCl, pH 7.4, containing 500 i^l Tween 
20/L. 
Carbonate-Bicarbonate Buffer 
15 mM sodium carbonate, 35 mM sodium bicarbonate, pH 9.6, containing 2 
mM magnesium chloride. 
Citrate-Phosphate Buffer 
15 mM citric acid, 50 mM Na2HP04, pH 5.0. 
Substrate 
(i) 500 |a,g p-nitrophenyl phosphate (p-NPP)/ml of carbonate-bicarbonate 
buffer. 
(ii) Procedure 
An enzyme linked immunosorbent assay (ELISA) was carried out on 
polystryrene plates with slight modification (AH and Alam, 2002; Dixit and Ali, 2004; 
Dixit et al, 2005; Habib el al., 2005; Khan et al, 2005; Mansoor et al, 2005; Khan 
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and Ali, 2006). Polystryrene polysorp immunoplates were coated with 100 i^ L of 
native or modified HSA (10 |ig/ml). Polystryrene maxisorp immunoplates were 
coated with 100 |aL of plasmid DNA or native calf thymus DNA (2.5|ig/ml). The 
plates were coated for 2 h at 37°C and overnight at 4°C. Each samples was coated in 
duplicate and half of the plates served as control devoid of only antigen coating. 
Unbound antigen was washed thrice with TBS-T (20 mM Tris, 150 mM NaCl, pH 7.4 
containing 0.05% Tween-20) and unoccupied sites were blocked with 2% fat free 
milk in TBS (10 mM Tris, 150 mM NaCl, pH 7.4) for 4-6 h at 37°C. After incubation 
the plates were washed four times with TBS-T. The test serum serially diluted in 
TBS-T or affinity purified IgG in TBS (100 |.iL/well) was adsorbed for 2 h at 37°C 
and overnight at 4°C. Bound antibodies were assayed with anti-rabbit/anti-human IgG 
alkaline phosphatase conjugate using p-nitrophenyl phosphate as substrate. The 
absorbance of each well was monitored at 410 nm on an automatic microplate reader. 
Each sample was run in duplicate. The control wells were treated similarly but were 
devoid of antigen. Results were expressed as a mean of Atest—Acontroi-
(b) Competition ELISA 
The antigenic specificity of the antibodies was determined by 
competition ELISA (Dixit and Ali, 2001; Hasan et al, 1990; Dixit and Ali, 2004; 
Dixit et al, 2005; Habib et al., 2005; Khan et al., 2005; Mansoor et al, 2005; Khan 
and Ali, 2006). Varying amounts of inhibitors (0-20 |ig/ml) were mixed with a 
constant amount of antiserum or IgG. The mixture was incubated at room temperature 
for 2 hrs. and overnight at 4 °C. The immune complex thus formed was coated in the 
wells instead of the serum/IgG. The remaining steps were the same as in direct 
binding ELISA. Percent inhibition was calculated using the formula: 
•^inhibited 
Percent inhibition = 1 — X 100 
•'^uninhibited 
(c) Immunodiffusion 
Immunodiffusion (ID) was carried out by Ouchtertony Double 
Diffusion System with slight modification (Ouchtertony , 1949). Six ml of 1% molten 
agarose in PBS, containing 0.1% sodium azide, was poured onto a glass petridish and 
50 
allowed to solidify at room temperature. Wells of 5 mm diameter were cut into the 
hardened gel and an appropriate concentration of antigen and antibody were placed in 
the wells. The petridish was allowed to stand in a moist chamber at room temperature 
for 48-72 hrs. The gel was washed with 5% sodium citrate to remove non-specific 
precipitin lines and the result was analyzed visually. 
(d) Formation and Quantification of Immune Complexes 
The assay was carried out in eppendorf microfuge tubes as described 
earlier with some modifications (Dixit and Ali, 2004). Increasing amount of antigen 
(0-100 ^g) was added to a constant amount of immune or SLE IgG (120 |Lig) in an 
assay volume of 200 i^T. Preimmune or normal human IgG was used as control. The 
mixture was incubated for 2 h at 37 °C and overnight at 4 ^ . The immune complexes 
were pelleted and supernatant was carefully taken out to fresh assay tube. To 
supernatant which contains unbound antigen and unbound IgG was added Protein A-
Sepharose beads and the mixture incubated for 2 h at room temperature. The beads 
were pelleted and the unbound antigen in the supernatant was estimated 
spectrophotometrically. IgG bound to Sepharose beads was eluted with 0.58% glacial 
acetic acid containing 0.85%) sodium chloride. After five minutes of incubation, the 
pH of supernatant was adjusted by 1.0 M Tris, pH 7.5. The eluted IgG was estimated 
by spectrophotometry and represent unbound IgG. Apparent affinity constant was 
determined by Langmiur plot (Langmuir, 1981; Benefield et al., 1982). 
The Langmuir equation is commonly written as follows (Langmuir, 1918); 
x/m = abC/l + aC 
where, 
x = amount of material adsorbed or bound antigen. 
m = weight of adsorbent or bound IgG. 
C = concentration of material remaining in the solution after adsorption is 
complete or unbound antigen. 
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a = Langmuir apparent antibody affinity constant, 
b = Langmuir equilibrium constant. 
Taking the reciprocal of both sides of the above defined Langmuir equation 
l / ( x / m ) = l / b + l / a b C 
If adsorption follows the Langmuir analysis, a linear trace should result when the 
quatity l/(x/m) is plotted against 1/C as shown in the below figure. Values of the 
constants a and b can be determined from the slope and intercept of the plot. 
S l o p e = 1/ab 
I n t e r c e p t = 1/b 
1/C 
Plot of Langmuir equation 
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(e) Band shift assay 
For the visual detection of antigen antibody binding and immune 
complex formation, gel retardation assays were performed (Sandford et al, 1988; 
Dixit and Ali, 2001; Dixit and All, 2004; Dixit et a/., 2005; Habib et al, 2005; Khan 
et al., 2005; Mansoor et al, 2005; Khan and Ali, 2006). A constant amount of antigen 
(native and modified HSA) was incubated with varying amounts of IgG in PBS, pH 
7.4 for 2 hrs. at 37 °C and overnight at 4 °C. One-forth volume of 'sample' dye was 
added to the mixture and electrophoresed on 7.5% native PAGE with 2.5% stacking 
gel for 3-8 h with 80V at 4°C. The gels were visualized using silver nitrate and/or 
coomassie brilliant blue (R-250) staining. Agarose gel electrophoresis was performed 
in case of plasmid DNA, native ctDNA and ROS-DNA. Immune complexes were 
prepared by incubating constant amount of DNA with varying amounts of IgG in PBS 
for 2 h at 37°C and overnight at 4°C or overnight at 37°C. The 1% or 0.8% agarose gel 
was run with TAE buffer (40 mM Tris acetate-9 mM EDTA, pH 8.0) at 30 mA for 1.5 
- 2.5 h. The gels were stained with ethidium bromide (0.5 |ig/ml), viewed by 
illumination under UV light. 
Statistical Analysis 
Data are presented as mean ± SD or mean ± SE. Significance of differences 
from control values were determined with the Student's r-test (Statgraphics, Origin 
6.1; MS-Excel; Sigma 2000). A value of/» < 0.05 was considered to indicate 
statistical significance. 
'^suCts 
Reactive Oxygen Species Modification of Human Serum Albumin 
A solution of human serum albumin (HSA) in PBS, pH 7.4 was modified with 
reactive oxygen species. UV irradiation (254 nm) in the presence of hydrogen 
peroxide is known to generate hydroxyl radical. The irradiated samples were dialyzed 
against PBS to remove excess hydrogen peroxide. The major ROS produced by this 
procedure would be hydroxyl radical (OH). 
The ultraviolet spectrum was recorded on a Shimadzu spectrophotometer UV 
240 in the wavelength range of 200 nm to 400 nm. Figure 1 shows the UV absorption 
spectra of reactive oxygen species modified HSA (ROS-HSA) with characteristic 
hyperchromicity (59.2 %) at 280 nm. The perturbations incurred on HSA as a 
consequence of reactive oxygen species were also analyzed by UV difference spectral 
scanning (Fig. 1 inset). The UV difference spectrum of ROS modified HSA recorded 
against native HSA reiterated the results of UV absorbance measurements. 
Circular Dichroism of Modified HSA 
The circular dichroism (CD) spectra of the native and ROS-HSA was recorded 
in the wavelength range of 200 nm to 250 nm (far UV-CD) and 250 nm to 300 nm 
(near UV-CD). 
Far-UV CD of ROS-Modified HSA 
In order to get information about the secondary structure of the protein, far-
UV CD measurements were performed. Figure 2 shows the far-UV CD of native and 
ROS-HSA. HSA in the native state contained around 58% alpha-helical structure as 
determined from the ellipticity value at 222 nm by the method of Chen et al. (1972), a 
values in agreement with the value reported by other workers (Reed et al, 1975). The 
curve for hydroxyl-modified HSA showed an increase in the ellipticity value, 
indicating the loss of- 30% alpha-helical structure from the native state (Table 4). 
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Figure 1. UV absorption spectra of native (—) and hydroxy! radical modified (—) 
HSA. Inset: UV difference spectra of'OH-modified HSA recorded against 
native HSA as a reference. 
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Figure 2. Far UV circular dichroic spectra of native (—) and ROS-modified (—) 
HSA. The samples were in PBS, pH 7.4 at a concentration of 3 \iM. 
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TABLE 4 
Characterization of native and ROS-modified HSA under identical experimental 
conditions 
Parameter Native HSA ROS-HSA Modification 
UV absorbance at 280 nm 0.1 
MREat222nm 19943.01 
(deg cm mof ) 
MREat262nm 95.7 
(deg cm mof ) 
MRE at 268 nm 76.3 
(deg cm mof ) 
Alpha helix -58 % 
Fluorescence intensity 78.7 
(At Ext. 295 and Em. 340 
nm) 
Fluorescence intensity 150.2 
(At Ext. 280 and Em. 320 
nm) 
HPLC measurements 
(a) Area of major peak (cm ) 5.8 
(b) Elution volume at major 20.0 
peak (ml) 
(c) Concentration of NaCl, 0.19 
M (elution of major peak) 
Melting temperature, °C 58 
0.27 59.2 % hyperchromicity 
10826.21 
31.9 
13.7 
-28 % 
22.5 
40.0 
12.6 
23.8 
0.27 
60.5 
-30 % loss 
71.4% loss 
73.3 % loss 
Carbonyl contents 
(nmol/mg protein) 
5.1 43.1 88.2% increase 
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Near-UV CD of ROS-Modified HSA 
To study the structural alterations in more detail, the CD measurements in the 
near-UV region, which infer to tertiary structure. Figure 3 shows the near-UV CD 
spectra of native and ROS-HSA. HSA in the native state showed two minima at 262 
nm and 268 nm, with shoulders at 275 nm and 292 nm, this is the characteristic of 
disulfide and aromatic chromophores (Lee and Hirose, 1992). Upon ROS 
modification, there was a loss of signal and fine structure at 275 nm and 292 nm; 
nonetheless the protein retained the two minima at 262 and 268 nm (Table 4) 
indicating the loss of significant proportion of tertiary structure. 
Fluorescence Spectroscopy 
HSA has a single tryptophanyl residue (Trp-214) located in domain-Il. To 
examine the conformational variations around this residue in HSA and HSA-DOM 11, 
protein was excited at 295 nm. 
The oxidafion of tryptophan residue on ROS-damaged HSA was evident by 
the loss of 71.4% fluorescence intensity at 340 nm using an excitation wavelength of 
295 nm (Fig. 4a; Table 4). The damage of tryptophan was confirmed by the loss of 
73.3% fluorescence intensity at 320 nm using an excitation wavelength of 280 nm 
(Fig. 4b; Table 4). 
Polyacrylamide Gel Electrophoresis 
SDS-PAGE of nafive and ROS-HSA under reducing and non-reducing 
conditions are shown in Figure 5. Intensity of ROS-HSA band becomes lighter as 
compared to native HSA on damaged by OH radical. Both native and ROS-HSA 
were also run on 7.5% native PAGE (data not given). The dimeric band of native 
HSA has almost completely disappeared upon ROS modification and the intensity of 
monomeric band of ROS-HSA becomes lighter as compared to native HSA. 
Absorption-Temperature Scan 
During temperature-induced denaturation, the protein absorbance changes 
with temperature until the process of unfolding is complete. Thermal melting profile 
of native and ROS-damaged HSA showed mehing temperature (Tm) of native and 
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Figure 3. Near UV circular dichroic spectra of native (—) and ROS-modified (—) 
HSA. The samples were in PBS, pH 7.4 at a concentration of 20 |aM. 
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Figure 4. Fluorescence emission spectra of native (—) and ROS-modified(—) HSA. 
Protein was in PBS, pH 7.4. The excitation wavelength was 295 nm (a) 
and 280 nm (b). 
60 
1 2 3 1 2 34 
66,000 
45,000 
36,000 
20,100 
^ ^ 
m 
- * 
^ 
" 
^ 
« ^ 
^ 
^ 
(a) (b) 
Figure 5. (a) SDS-polyacrylamide gel electrophoresis of native (lane 2) and ROS-
modified (lane 3) HSA under reducing conditions. Lane 1 contains SDS-
molecular weight markers. HSA, ROS-HSA and all marker proteins were 15 
Ug each. Electrophoresis was carried out on 12% gel for 3 h at 50 volts. 
(b) SDS-polyacrylamide gel electrophoresis of native (lane 2) and ROS-
modified (lane 3) HSA under non-reducing conditions. Lane 1 and 4 contain 
SDS-molecular weight markers. HSA, ROS-HSA and all marker proteins 
were 30 )j,g each. Electrophoresis was carried out on 7.5% gel for 4 h at 50 
volts. 
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modified HSA as 58°C and 60.5°C, respectively (Fig. 6). The complete unfolding of 
native and ROS-damaged HSA was occurred at 70°C and 85°C, respectively. After 
these temperatures both protein samples showed precipitation or aggregation as 
abnomal increase in their absorbance was noticed. 
High Performance Liquid Chromatography 
HPLC elution profile of native and ROS-modified HSA occurred at different 
salt concentration, on resource Q anion exchange column. The native protein eluted as 
a single sharp peak, whereas ROS-modified HSA eluted at a high NaCl concentration 
in two minor and a major broad peak (Fig. 7). HPLC measurements of native and 
hydroxyl modified HSA has been summarized in Table 4. 
Estimation of Carbonyl in ROS-Modified HSA 
Oxidation-induced carbonyl formation in HSA has been presented in Figure 8. 
Treatment with OH radical generate carbonyl contents (± SD) of 41.1 ±2.3 nmol/mg 
of protein at 15 niM of H2O2 and it was increased to 43.1 ± at 31 mM of H2O2. The 
carbonyl contents was found to be 45.8 ± 5.9 nmol/mg of protein at 62 mM of H2O2. 
The period of UV irradiation was kept constant. 
The oxidation of ROS-HSA was further evident by the increase of 88.2 % 
carbonyls contents (Table 4). The generation of hydroxyl radical was confirmed by 
using mannitol and DMSO, specific quenchers of 'OH radicals. The data showed 
decrease in carbonyl formation in the presence of mannitol and DMSO, whereas high 
carbonyl formation occurred in the absence of these quenchers (Fig. 9). The 
modification of HSA by hydroxyl radical has been summarized in Table 4. 
Antigenicity of ROS-Modified HSA 
The antigenicity of the hydroxyl modified HSA was probed by inducing 
antibodies in rabbits. The antigenic specificity of the induced antibodies was assayed 
by direct binding and competition ELISA, immunodiffusion and immunoprecipitin 
titration. The binding of these antibodies to the immunogen was further substantiated 
by band shift assay. 
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Figure 6. Themral denaturation profile of native (•) and ROS-modified (•) HSA. 
The samples were in PBS, pH 7.4 at a concentration of 3 [iM. 
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Figure 7. Elution profile of native (—) and ROS-modified (—) HSA on HPLC 
resourse Q anion exchange column. The samples were in Tris, pH 7.4. 
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Figure 8. Carbonyl formation in ROS-modified HSA. HSA (15 ^M) was UV 
irradiated for 30 min with the indicated concentration of H2O2. Each point 
represents the mean ± S.D. of three independent assays. 
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Figure 9. Carbonyl contents in native HSA (bar 1), ROS-HSA (bar 2), ROS-HSA in 
presence of 286 mM mannitol (bar 3) and ROS-HSA in presence of 286 
mM DMSO (bar 4). The protein concentration was 15 \xM. Each histogram 
represents the mean ± S.D. of two independent assays. 
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Antibodies Against Native and ROS-Modified HSA 
Direct binding ELISA showed that ROS-modified HSA is a potent 
immunogen inducing high titre (> 1 : 12800) antibodies, whereas with native HSA 
the titre was low (~ 1 : 6400). Preimmune serum serve as negative control did not 
showed appreciable binding with the respective immunogens (Fig. 10). The 
specificity of induced antibodies for antigenic determinants on ROS-modified and 
native HSA was evaluated by competitive binding assay. A maximum of 75% 
inhibition in antibody binding was recorded at an inhibitor (ROS-HSA) 
concentration of 20 |Jg/ml (Fig. 11a). The concentration of the competitor required 
for 50% inhibition was 0.25 |Jg/ml. Induced antibodies against native HSA 
showed 7 Wo inhibition at 20 Mg/rnl of immunogen concentration (Fig. lib). The 
concentration of the competitor (native HSA) required for 50%) inhibition was 8.0 
|jg/ml. 
The antibodies against ROS-HSA and HSA were found to be precipitating as 
detected by immunodiffusion (Fig. 12 a,b). 
Purification and Binding Characteristics of Immune IgG 
Immunoglobulin G against ROS-HSA and HSA was isolated by affinity 
chromatography on Protein A-Sepharose CL-4B column (Fig. 13). IgG from 
preimmune sera was also purified. The purity of the IgG was ascertained by SDS-
polyacrylamide gel electrophoresis under non-reducing condition (Fig. 13 inset). 
The affinity purified IgG migrated as a single band. 
Direct binding ELISA of the purified IgG showed strong binding with the 
respective immunogen (Fig. 14). Preimmune IgG showed negligible binding 
under identical conditions. The specificity of the affinity purified IgG was 
checked by competitive inhibition assay. A maximum of 97%) inhibition of anti-
ROS-HSA IgG and 90%) inhibhion of anti-HSA IgG with the respective 
immunogens was observed (Fig. 15). Fifty percent inhibition was achieved at an 
inhibitor concentration of 0.2 |Jg/ml in case of ROS-HSA, while 0.8 \Jg/ml was 
required for native HSA. 
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Figure 10. Level of induced antibodies against ROS-modified and native HSA. 
Direct binding ELISA of (a) ROS-HSA and (b) HSA with immune 
(A) and preimmune (A) sera. Microtitre plates were coated with the 
respective antigen (10 |ig/ml). Each point represents a mean ± S.D. of 
two independent assays. 
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Figure 11. (a) Inhibition ELISA of immune (A) and preimmune (A) sera against 
ROS-modified HSA. The ROS-HSA was used as an inhibitor. The 
microtitre plates was coated with ROS-HSA (10 |ig/ml). 
(b) Inhibition ELISA of immune (A) and preimmune (A) sera against 
native HSA. The native HSA was used as an inhibitor. The microtitre 
plates was coated with HSA (10 |ig/ml). Each point represents a 
mean ± S.D. of two independent assays. 
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Figure 12. Ouchterlony double immunodiffusion of (a) anti-ROS-HSA antibodies with 
ROS-HSA (b) anti-HSA antibodies with HSA. The central well contains 
antigen where as, well number 1 to 6 contain neat, 1:2,1:4,1: 8,1: 16 and 1: 
32 diluted immune sera. 
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Elution profile of (a) anti-ROS-HSA IgG and (b) anti-HSA IgG on Protein-A 
Sepharose CL-4B affinity column. Inset: SDS-PAGE of purified IgG on 7.5% 
polyacrylamide gel. 
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Figure 14. Binding of affinity purified (a) anti-ROS-HSA IgG (•) and pre-immune 
IgG (D) to ROS-HSA and (b) anti-HSA IgG (A) and pre-immune IgG 
(A) to native HSA. The microtitre plates were coated with the respective 
antigens (10 |ig/mi). Each point represents a mean ± S.D. of two 
independent assays. 
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Immuno-crossreactivity of Anti-ROS-HSA Antibodies 
The antigenic specificity of the induced anti-ROS-HSA antibodies was 
characterized by competition inhibition assay. A maximum of 96.8% inhibition of 
the anti-ROS-HSA IgG with the immunogen as inhibitor was observed (Fig. 15a). 
Competition experiments with native HSA showed 47.8% inhibition at 20 \Jig/ml 
(Fig. 15a). The anti-ROS-HSA antibodies exhibited a variable recognition of 
plasmid DNA, ROS-plasmid DNA and ROS-chromatin in competition ELISA. 
Native chromatin and plasmid DNA showed maximum inhibition of 37.3 % and 
56.6%, respectively and 17 |Jg/ml of plasmid DNA was required for 50% 
inhibition, whereas the ROS-modified conformers of chromatin and plasmid DNA 
showed maximum inhibition of 74.6%) and 61.7%o, respectively and 1.5 pg/ml and 
17 \Jg/ml were required for their 50% inhibition, respectively (Fig. 16a). 
Glycated HSA and fibrinogen showed moderate inhibitions of 34.5% and 
39.2%, respectively, whereas ROS conformers of glycated HSA showed 
negligible inhibition of 12.4%) (Fig. 17a). Native hemoglobin, ROS-glycated 
hemoglobin showed negligible inhibition of 28% and 28.3%, respectively, 
whereas ROS-modified hemoglobin and glycated-hemoglobin showed moderate 
inhibition of 35.4% and 33.3%, respectively (Fig 18a). Transferrin, y-globulin and 
ROS-modified y-globulin were non-inhibitory (20.2%, 20.2% and 21.4%, 
respectively), whereas ROS-transferrin showed a moderate inhibition of 46.4% 
(Fig. 19a). The antigen binding specificity of anfi-ROS-HSA antibodies has been 
summarized in Table 5. 
Immuno-crossreactivity of Anti-HSA Antibodies 
Competition ELISA with anti-HSA IgG showed a maximum inhibition of 
90.2%) with the immunogen as inhibitor. Only 0.8 |Jg/ml of immunogen was 
required for 50% inhibition in antibody binding. The induced antibodies partially 
recognized ROS-modified HSA as it showed a maximum inhibition of 53.1%) and 
10 |Jg/ml was required for 50% inhibition of antibody binding (Fig. 15b). Native 
chromatin and plasmid DNA showed maximum inhibition of 42.4% and 34.1%), 
respectively, whereas ROS-chromatin and ROS-plasmid showed maximum 
inhibition of 38.1% and 30.4%, respectively (Fig. 16b). 
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Figure 15. (a) Inhibition of anti-ROS-HSA IgG binding to ROS-HSA. The inhibitors 
were ROS-HSA (•) and HSA (D). The microtitre plates were coated with 
ROS-HSA (10 Mg/ml). (b) Inhibition of anti-HSA IgG binding to HSA. 
The inhibitors were HSA (A) and ROS-HSA (A). The microtitre plates 
were coated with HSA (10 (ag/ml) Each point represents a mean ± S.D. of 
two independent assays. 
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Figure 16. Inhibition of (a) anti-ROS-HSA IgG and (b) anti-HSA IgG binding to the 
respective antigens by ROS-chromatin (•), chromatin (D), ROS-plasmid 
(A) and plasmid (A) DNA. The microtitre plates were coated with the 
respective antigens (10 pg/ml). Each point represents a mean ± S.D. of two 
independent assays. 
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Figure 17. Inhibition of (a) anti-ROS-HSA IgG and (b) anti-HSA IgG binding to the 
respective antigens by ROS-glycated (•), glycated (D) HSA and fibrinogen 
(A). The microtitre plates were coated with the respective antigens (10 
|ag/rail). Each point represents a mean ± S.D. of two independent assays. 
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Figure 18. Inhibition of (a) anti-ROS-HSA IgG and (b) anti-HSA IgG binding to the 
respective antigens by ROS-hemoglobin (•), hemoglobin (n), ROS-
glycated (A) and glycated (A) hemoglobin. The microtitre plates were 
coated with the respective antigens (10 |ig/ml). Each point represents a 
mean ± S.D. of two independent assays. 
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Figure 19. Inhibition of (a) anti-ROS-HSA IgG and (b) anti-HSA IgG binding to the 
respective antigens by ROS-transferrin (•), transferrin (n), ROS-y-
globulin (A) and y-globulin (A). The microtitre plates were coated with 
the respective antigens (10 )ag/ml). Each point represents a mean ± S.D. of 
two independent assays. 
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TABLE 5 
Antigen binding specificity of anti-ROS-HSA IgG 
Inhibitors 
ROS-HSA 
Native HSA 
Chromatin 
ROS-Chromatin 
Plasmid DNA 
ROS-Plasmid DNA 
Glycated HSA 
ROS-Glycated HSA 
Fibrinogen 
Hemoglobin 
ROS-Hemoglobin 
Glycated-Hemoglobin 
ROS-Glycated 
Hemoglobin 
Transferrin 
ROS-Transferrin 
y-Globulin 
ROS- Y-Globulin 
Max % inhibition 
at 20 |ig/ml 
96.8 ±1.4 
47.8 ±2.4 
37.3 ±3.8 
74.6 ± 2.2 
56.6 ±2.8 
61.7±3.0 
34.5 ±3.1 
12.4 ±2.3 
39.2 ±2.3 
28.0 ±2.2 
35.4 ±1.9 
33.3 ±2.9 
28.3 ±3.6 
20.2 ±2.1 
46.4 ±3.8 
20.2 ±1.9 
21.4±3.8 
Concentration for 
50% inhibition 
(Hg/ml) 
0.2 
-
-
1.5 
17.0 
17.0 
-
-
-
-
-
-
-
-
-
-
-
% Relative 
affinity 
100 
-
-
13.3 
1.2 
1.2 
-
-
-
-
-
-
-
-
-
-
-
The results represent mean ± S.D. of two independent assays. The ELISA plates were 
coated with ROS-HSA (10 \ig/m\) 
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Glycated HSA, ROS-glycated HSA and fibrinogen were non-inhibitory showing 
inhibition of 25.2%, 20.4% and 26.8%, respectively (Fig. 17b). Hemoglobin and 
glycated-hemoglobin showed negligible inhibition of 15.2% and 24.8%, 
respectively, whereas their ROS modified conformers were inhibitory to the 
extent of 16.4% and 25.1%), respectively (Fig. 18b). Transferrin, ROS-transferrin, 
y-globulin and ROS-y-globulin were non-inhibitory showing inhibition to 26.1%, 
18.4%), 22.1% and 19.1%, respectively (Fig. 19b). Table 6 summaries the data of 
the binding characteristics of anti-HSA IgG as determined by inhibition ELISA. 
Band Shift Assay 
The interaction of anti-ROS-HSA IgG and anti-HSA IgG with their 
immunogens was ascertained visually by gel retardation assays on native PAGE. 
Figure 20 shows the binding of anti-ROS-HSA IgG to ROS-HSA and Figures 21 
shows the binding of anti-HSA IgG to HSA. On increasing the amount of immune 
IgG with constant amount of the respective antigens, the increase in the formation 
of high molecular weight immune complexes was clearly evident in wells, which 
resulted in retarded mobility and corresponding decrease in the intensity of 
unbound antigen. 
Band shift assay was also employed to visualize the interaction of native and 
ROS modified calf thymus DNA to anti-ROS-HSA IgG, as well as to anti-HSA 
IgG. A constant amount of native and ROS-DNA was incubated with increasing 
amounts of anti-ROS-HSA IgG and with anti-HSA IgG for overnight at 4°C. 
Figure 22 (a) shows the binding of anti-ROS-HSA IgG to native DNA. With 
increasing concentration of IgG there is corresponding increase in the formation 
of high molecular weight complexes as evident in wells. Figure 22 (b) shows the 
binding of anti-ROS-HSA IgG to ROS-DNA. With increasing concentration of 
IgG there is a corresponding increase in the formation of high molecular weight 
immune complexes which resulted in retarded mobility and corresponding 
decrease in the fluorescence intensity of unbound antigen. Anti-HSA IgG 
incubated under identical experimental conditions neither show immune complex 
formation with native DNA nor with ROS-DNA (Fig. 23 a and b). 
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TABLE 6 
Antigen binding specificity of anti-HSA IgG 
Inhibitors Max. % inhibition Concentration for % Relative 
at 20 \xg/m\ 50% inhibition affinity 
(l^g/ml) 
Native HSA 
ROS-HSA 
Chromatin 
ROS-Chromatin 
Plasmid DNA 
ROS-Plasmid DNA 
Glycated HSA 
ROS-GIycated HSA 
Fibrinogen 
Hemoglobin 
ROS-Hemoglobin 
Glycated-Hemoglobin 
ROS-Glycated 
Hemoglobin 
Transferrin 
ROS-Transferrin 
y-Globulin 
ROS- Y-Globulin 
90.2 ±3.4 
53.1 ±2.7 
42.4 ±3.2 
34.1 ±2.8 
38.1 ±3.4 
30.4 ±2.2 
25.2 ±3.8 
20.4 ±2.6 
26.8 ±2.2 
15.2±3.9 
16.4 ±3.2 
24.8 ±2.8 
25.1 ±2.2 
26.1±3.8 
18.4 ±2.9 
22.1 ±2.6 
19.1 ±3.4 
0.8 
[0.0 
100 
8.0 
The results represent mean ± S.D. of two independent assays. The ELISA plates were 
coated with native HSA (10 ng/ml) 
81 
1 2 3 4 5 6 
Figure 20. Band shift assay of anti-ROS-HSA IgG binding to ROS-HSA. ROS-HSA 
(25 i^g each) was incubated with buffer (lane 1) and 10, 20, 30 and 40 pg 
IgG through lanes 2 to 5, respectively for 2 h at 37°C and overnight at 4°C. 
Lane 6 contains IgG (15 |Jg) alone. Electrophoresis was performed on 
native PAGE on 7.5% gel with 2.5% stacking gel. The gel was run at 4°C for 
4hat80V. 
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Figure 21. Band shift assay of anti-HSA IgG binding to HSA. HSA ( 35 |Jg each) was 
incubated with buffer (lane 1) and 35,45, 55 and 65 pg IgG through lanes 2 
to 5, respectively for 2 h at 37°C and overnight at 4°C. Lane 6 contains IgG 
(30 |Jg) alone. Electrophoresis was performed on native PAGE on 7.5% gel 
with 2.5% stacking gel. The gel was run at 4°C for 4 h at 80 V. 
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Figure 22. (a) Band shift assay of anti-ROS-HSA IgG binding to native ctDNA. Native 
DNA ( 0.5 |jg each) was incubated with buffer (lane 1) and 30, 90 and 120 
pg IgG through lanes 2 to 4, respectively for overnight at 37°C. 
Electrophoresis was performed on 0.8% agarose for 2.5 h at 30 mA. 
(b) Band shift assay of anti-ROS-HSA IgG binding to ROS ctDNA. ROS-
DNA ( 0.5 |jg each) was incubated with buffer (lane 1) and 30, 90 and 120 
(Jg IgG through lanes 2 to 4, respectively fo.' overnight at 37°C. 
Electrophoresis was performed on 0.8% agarose for 1.5 h at 30 mA. 
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(b) 
Figure 23. (a) Band shift assay of anti-HSA IgG binding to native ctDNA. Native 
DNA (0.5 |Jg each) was incubated with buffer (lane 1) and 30, 90 and 120 
fjg IgG through lanes 2 to 4, respectively fof overnight at 37°C. 
Electrophoresis was performed on 0.8% agarose for 2.5 h at 30 mA. 
(b) Band shift assay of anti-HSA IgG binding to ROS ctDNA. ROS-DNA ( 
0.5 |Jg each) was incubated with buffer (lane 1) and 30,90 and 120 ^ Jg IgG 
through lanes 2 to 4, respectively for overnight at 37°C. Electrophoresis 
was performed on 0.8% agarose for 2 h at 30 mA. 
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Evaluation of Antibody Affinity 
The antigen-antibody interaction was also characterized by quantitative 
precipitin titration. Varying amounts of modified and unmodified HSA (0 to 100 
pg) were mixed with 120 [jg of respective immune IgG and incubated for 2 h at 
37°C and overnight at 4°C. A maximum of 25 |Jg of ROS-HSA was bound by 
87.5 |Jg of anti-ROS-HSA IgG while in native HSA a maximum of 21 |Jg of 
antigen was bound by 74.4 |Jg of anti-HSA IgG. Langmuir plot was used to 
evaluate the apparent antibody affinity constants and the values for ROS-modified 
and native HSA were found to be 12.5 x 10^  M"' (Fig. 24) and 1.2 x 10^  M'' (Fig. 
25), respectively. 
Isolation of Plasmid Bluescript DH5 a "KS" 
Plasmid DNA was purified from E. Coli strain DH5 Q "KS" by using Qiagen 
plasmid mega kit as described in materials and methods. The isolated DNA was 
subjected to agarose gel electrophoresis (Fig. 26). 
RecognitioM of ROS-HSA by SLE Autoantibodies 
Sera from 59 female SLE patients and 22 normal human subjects were tested 
for binding to native calf thymus and plasmid DNA, native and ROS modified 
HSA by direct binding ELISA. Majority of SLE sera (31/59) showed strong 
binding to ROS-HSA over native HSA at 1:100 serum dilution (p<0.001). No 
appreciable binding was observed with the normal subjects. Both nucleic acid 
samples showed significant (p<0.001) binding to SLE sera as compared to NHS. 
The average absorbance at 410 nm (± SD) of selected 31 SLE sera binding to 
native and ROS-damaged HSA was 0.55 ± 0.03 and 0.99 ± 0.3, respectively and 
the average absorbance (± SD) of 54 SLE sera binding to native calf thymus and 
plasmid DNA was 0.75 ± 0.4 and 0.90 ± 0.3, respectively whereas the average (± 
SD) of 22 normal human sera binding to both protein and both nucleic acid 
antigens was 0.29 ± 0.08 (Fig. 27). 
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E 
Figure 24. Determination of apparent anti-ROS-HSA antibody affinity constant 
towards ROS-HSA by Langmuir plot. 
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E 
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Figure 25. Determination of apparent anti-HSA antibody affinity constant towards 
native HSA by Langmuir plot. 
^^^^H 1 
1 
H^HHi 
Mti/ 
1 
Figure 26. Agarose gel electrophoretic patter of isolated plasmid Bluescript DH5 a 
"KS" DNA. Electrophoresis was performed on 1 % agarose gel at 30 mA 
for 2 h. The amount of DNA used was 0.5 |Jg. The sample was run in 
duplicate. 
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Figure 27. Direct binding ELISA of 1:100 diluted SLE serum samples. The 
microtitre plates were individidually coated with nDNA, plasmid DNA 
(2.5 ng/ml), HSA and ROS-HSA (10 ^g/ml). Binding of SLE sera to 
native HSA (bar 2), ROS-HSA (bar 3), nDNA (bar 4) and plasmid 
DNA (bar 5). The number of serum samples were 31 (HSA, ROS-
HSA) and 54 (nDNA, plasmid DNA). Normal human serum pool (bar 
1) with either of antigens. Standard deviation has been indicated with 
each bar. 
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The binding specificity of SLE autoantibodies was evaluated by compefition 
ELISA using plasmid DNA, native HSA and ROS-HSA as inhibitors (Fig. 28-32). 
The microtitre plates were coated with plasmid DNA. The average percent 
inhibition (± SD) of 31 SLE sera binding to plasmid DNA, native and ROS 
modified HSA was 46.8 ± 6.3, 33.5 ± 6.2 and 55.1 ± 7.4, respecfively (Table 7). 
On comparing the inhibition values of native and ROS modified HSA, the 
coefficient of variation and /?-value indicates significant difference in the 
inhibitory capacity of these antigens. The correlation coefficient (r) between ROS 
and native HSA (r = 0.48, p<0.01), reiterates increased recognition of ROS-HSA 
by SLE anti-DNA autoantibodies. 
To substantiate the above results, IgG were isolated from three high binding 
SLE sera and three normal healthy subjects on a Protein-A Sepharose 4B affinity 
column (Fig. 33 a,b). The purified IgGs from SLE and normal human sera were 
found to be eluted in a single symmetrical peak. The homogeneity of the IgG was 
checked by SDS-PAGE under non-reducing conditions and was found to migrate 
as a single band (Fig. 33 inset). Compefition ELISA (Fig. 34) was performed with 
isolated SLE IgG samples. ROS-damaged HSA, native HSA and plasmid DNA 
were used as inhibitors. The microtitre plates were coated with plasmid DNA. The 
average percent inhibition (± SD) at 20 |ig/ml of inhibitor concentration of three 
purified SLE IgG binding to ROS-HSA, nafive HSA and plasmid DNA was 74.03 
± 2.38, 41.15 ± 0.55 and 64.77 ± 2.41, respectively (Fig. 34), a ;7-value of <0.001 
indicates significant difference in the binding of ROS-damaged and native HSA. 
The results were similar to those obtained with serum (Table 7). 
Band Shift Assay 
The interaction of native and ROS-modified HSA with SLE autoantibodies 
was ascertained visually by gel retardation assay on native PAGE. Figure 35 
shows the binding of SLE IgG to ROS-HSA. The data showed difference in the 
mobility and corresponding decrease in the intensity of unbound antigen due to 
the formation of high molecular weight immune complexes. On increasing the 
concentration of SLE IgG with constant amount of ROS-HSA, the increase in the 
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Figure 28. Inhibition of SLE antibodies from SLE sera 1 - 3 (a) and 4 - 6 (b) binding 
to plasmid DNA. The inhibitors were ROS-HSA (•), HSA (•) and 
plasmid DNA (A). The microtitre plates were coated with plasmid DNA 
(2.5 (.ig/ml). Each point represents a mean ± S.E. of 3 independent assays. 
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Figure 29. Inhibition of SLE antibodies from SLE sera 7 - 9 (a) and 10 - 12 (b) 
binding to plasmid DNA. The inhibitors were ROS-HSA (•), HSA (•) 
and plasmid DNA (A). The micro titre plates were coated with plasmid 
DNA (2.5 ^g/ml). Each point represents a mean ± S.E. of 3 independent 
assays. 
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Figure 30. Inhibition of SLE antibodies from SLE sera 13 -15 (a) and 16 - 18 (b) 
binding to plasmid DNA. The inhibitors were ROS-HSA (•), HSA (•) 
and plasmid DNA (A). The microtitre plates were coated with plasmid 
DNA (2.5 M g^/ml). Each point represents a mean ± S.E. of 3 independent 
assays. 
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Figure 31. Inhibition of SLE antibodies from SLE sera 19-21 (a) and 22 - 24 (b) 
binding to plasmid DNA. The inhibitors were ROS-HSA (•), HSA (•) 
and plasmid DNA (A). The microtitre plates were coated with plasmid 
DNA (2.5 M-g/ml). Each point represents a mean ± S.E. of 3 independent 
assays. 
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Figure 32. Inhibition of SLE antibodies from SLE sera 25 -27 (a) and 2 8 - 3 1 (b) 
binding to plasmid DNA. The inhibitors were ROS-HSA (•), HSA (•) 
and plasmid DNA (A). The microtitre plates were coated with plasmid 
DNA (2.5 fig/ml). Each point in Fig.(a) represents a mean ± S.E. of 3 
independent assays and in Fig.(b) represents a mean ± S.E. of 4 
independent assays. 
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TABLE 7 
Competitive inhibition of SLE serum antibodies binding to native DNA, HSA 
and ROS-HSA 
SLE serum 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
MeaniSD 
(CV) 
Maximum percent 
Plasmid DNA 
45.7 
60.0 
40.0 
47.3 
39.2 
43.8 
56.0 
57.7 
51.2 
38.4 
53.2 
43.4 
39.8 
51.7 
40.0 
46.9 
49.5 
42.2 
59.0 
49.8 
43.1 
40.8 
52.3 
47.2 
43.3 
45.5 
42.4 
40.5 
39.2 
49.8 
54.2 
46.8±6.3 
(13.5) 
inhibition at 20 (ig/ml 
Native-HSA 
32.2 
38.2 
22.3 
29.8 
24.1 
37.5 
38.7 
33.3 
50.0 
35.5 
38.5 
32.5 
29.4 
33.1 
33.9 
43.3 
47.2 
33.3 
35.9 
26.1 
29.2 
27.3 
34.3 
32.8 
28.9 
32.0 
30.0 
28.4 
26.5 
29.2 
35.5 
33.2±6.2 
(18.7) 
ROS-HSA 
63.0 
67.5 
48.8 
66.7 
51.4 
50.7 
58.7 
54.3 
68.8 
49.1 
48.1 
61.1 
43.8 
44.6 
62.9 
50.5 
62.2 
65.5 
55.7 
45.2 
47.3 
55.3 
61.8 
46.0 
49.1 
55.2 
55.6 
58.2 
50.2 
59.2 
63.4 
55.1±7.4 
(13.4) 
Microtitre plates were coated with native plasmid DNA (2.5 |ig/ml). Student's t 
evaluation of significance: ROS-HSA V native HSA, p<0.001. The correlation 
coefficient (r = 0.483) also showed significance between them. 
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Figure 33. Elution profile of (a) SLE IgG and (b) normal human IgG on Protein A-
Sepharose CL-4B affinity column. Inset: SDS-PAGE of purified IgG on 
7.5% polyacrylamide gel. 
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Figure 34. Inhibhion of affinity purified SLE IgG binding to plasmid DNA. The 
inhibitors were ROS-modified HSA (•), native HSA (•) and plasmid 
DNA (A). The microfitre plates were coated with plasmid DNA (2.5 
|ag/ml). Each point represents a mean ± S.D. of three independent assays. 
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Figure 35. Band shift assay of SLE IgG binding to ROS-HSA. ROS-HSA (55 pg each) 
was incubated with buffer (lane 2) and 30, 40, 50 and 60 |Jg SLE IgG 
through lanes 2 to 5, respectively for 2 h at 37°C and overnight at 4°C. Lane 
6 contains IgG (30 |Jg) alone. Electrophoresis was performed on native 
PAGE on 7.5% gel with 2.5% stacking gel for 3 h with 80 Vat4°C. 
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formation of high molecular immune complexes was clearly evident in wells. 
Native HSA with SLE IgG did not showed either visible retardation in the 
mobility of unbound antigen or the formation of immune complexes under 
identical experimental conditions (data not given). Band shift assay was also 
performed for the recognition of plasmid DNA by SLE IgG (Fig. 36). The shift in 
electrophoretic mobility and corresponding decrease in fluorescence intensity of 
the unbound antigen was observed with increasing concentration of SLE IgG, 
keeping antigen concentration constant, high molecular weight immune 
complexes were visualized. 
Evaluation of SLE Antibody Affinity 
Increasing amount of native and ROS-modified HSA were added to 120 ^g of 
SLE IgG for the determination of apparent antibody affinity as described in 
materials and methods. A maximum of 10.2 i^ g of ROS-HSA was bound by 62 f^ g 
of IgG while in native HSA a maximum of 4.4 |ig of antigen was bound by 15 
pg of IgG . Langmuir plot was used to evaluate the apparent antibody affinity 
constants and the values for ROS-modified and native HSA were 10.3 X 10*^  M"' 
and 3.2 X 10^  M"', respectively (Fig. 37). 
Isolation of Human Serum Albumin 
Human serum albumin was isolated from normal human and SLE patient's 
blood as described in the materials and methods. About 10 mg protein was 
obtained from 0.5 ml of normal human and SLE patient's plasma. The preparation 
gave a single and almost symmetrical peak on a Sephacryl S-200 HR column (Fig. 
38) indicating a fair degree of size homogeneity. It had an elution volume 
identical to that of commercial HSA, the ratio of the elution volume to void 
volume (Ve/Vo) being 2.20 in all the three cases. The preparation was also found 
to be pure with respect to charge as evidenced by the electrophoretic pattern of 
purified HSAs under native conditions in which they gave a single band. The 
mobility of purified HSAs on 7.5% polyacrylamide gel is similar to that of 
commercial HSA (Fig. 38 inset). 
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Figure 36. Gel retardation assay of SLE IgG binding to native plasmid DNA. Native 
plasmid DNA (0.5 ^g each) was incubated with buffer (lane 1) and with 25, 
35,45, and 55 ^ ig SLE IgG through lanes 2 to 5, respectively for 2 h at 37°C 
and overnight at 4°C. Electrophoresis was performed on 1 % agarose gel for 2 
hat 30 mA. 
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Figure 37. Determination of apparent SLE IgG affinity constant towards native (•) 
and ROS-HSA (•) by Langmuir plot. 
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Figure 38. Elution profiles of purified HSA from normal human (T), SLE patient's (•) 
blood and commercial HSA (o) on Sephacryl S-200 HR column. Elution 
was performed with 0.06 M sodium phosphate buffer, pH 7.0, at a flow rate 
of 15 ml/h in 5 ml fractions. Protein in each fraction was monitored by the 
method ofLowrye? a/. (1951). 
Inset: Native PAGE of purified HSAs, and commercial HSA on 7.5 % gel. 
Lane 1 contains eluted commercial HSA (fraction no. 18), lane 2 and 3 
contain purified HSA from normal human (fraction no. 18) and SLE 
patients (fraction no. 18) blood, respectively. The amount of protein in all 
cases were 35 ng. 
104 
Level of Oxidation in Isolated Proteins 
The oxidation of a protein typically results in an increase in carbonyl contents. 
This is due to the oxidation of lys, arg, pro etc residues. The Data showed serum 
protein carbonyl contents were significantly {p < 0.01) increased in SLE patients, 
compared with normal subjects. The average carbonyl contents (±SD) of three 
independent assays of SLE serum protein and normal human serum protein were 
3.0 ± 0.05 and 2.2 ± 0.23 nmol/mg protein, respectively (Fig. 39). 
Further, to investigate the extent of alterations in the biological properties of 
HSA in SLE patients, HSA was isolated from SLE patients (SLE-HSA) and also 
from the normal subjects (NH-HSA) and their carbonyl contents were compared. 
The average carbonyl contents (±SD) of three independent assays of SLE-HSA 
and NH-HSA were 2.54 ± 0.06 and 1.62 ± 0.20 nmol/mg protein, respectively 
(Fig. 39). A p - value of < 0.05 indicates significant difference in the carbonyl 
contents of SLE-HSA and NH-HSA. The results were similar to those obtained 
with serum (Fig. 39). 
Detection of Anti-ROS-HSA Antibodies in Cancer Sera 
This study comprised of eighty one samples of patient's sera suffering from 
cancer of different organ / organ systems. Cancer sera were obtained after careful 
clinical examination of patients with proven histo-pathological diagnosis at J.N. 
Medical College Hospital, A.M.U., Aligarh and also from All India Institute of 
Medical Sciences, New Delhi. Sera from normal, healthy individuals served as 
negative control. 
The binding of circulating antibodies in cancer sera (at 1: 100 dilution) with 
native and ROS-HSA was assessed by direct binding ELISA. Fifty seven percent 
sera recognized ROS-HSA (Fig. 40). Out of eighty one samples, eleven sera were 
from patients with stomach cancer. Out of eleven sera, seven samples showed 
higher recognition towards ROS-HSA than native HSA. Four sera from patients of 
oral cancer were studied. Only one of them was found to be active for ROS-HSA, 
whereas all four were inactive for native HSA.Thirteen samples were from 
patients with lung cancer were collected, eight of them were showed higher 
binding towards ROS-HSA than native HSA. Remaining five were inactive for 
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Figure 39. Comparison of carbonyl contents in normal human serum proteins (bar 1), 
SLE serum proteins (bar 2), HSA from normal human (bar 3) and HSA from 
SLE patients (bar 4). Each histogram represents mean ± S.D. of three 
independent assays. 
106 
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Cancer Sera 
Figure 40. Direct binding ELISA of 1:100 diluted cancer serum samples to ROS-
modified (D) and native ( 8 ) HSA. The number of selected serum 
samples were 3 (stomach), 1 (oral), 4 (lung), 3 (chronic myeloid), 2 
(urinary bladder), 4 (breast), 1 (prostate), 3 (hepatocellular) and 10 
(NHS). Standard deviation has been indicated by a bar. The microtitre 
plates were coated with the respective antigens (10 ^ig/ml). 
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both native and ROS-HSA. Among the ten sera collected from patients with chronic 
myeloid leukemia, five were found to be more reactive towards ROS-HSA over 
native HSA. Whereas, remaining five were inactive for both native and ROS-HSA. Of 
the thirteen samples were collected from urinary bladder cancer patients, seven were 
showed strong binding to ROS-HSA over native HSA, six did not showed any 
binding to either of the antigens. Among the fifteen samples from patients with breast 
cancer, eight showed greater reactivity towards ROS-HSA than to its native form. 
While, remaining seven were inactive for both native and ROS-HSA. Three sera from 
patients of prostate cancer were studied, only one was found to be active for ROS-
HSA, whereas, remaining two were inactive for both the antigens. Twelve samples 
were from patients with hepatocellular carcinoma were tested, nine sera showed better 
binding to ROS-HSA over native HSA. Direct binding ELISA results have been 
summarized in Table 8. 
The reactivity of serum antibodies to native and ROS-HSA was also studied 
by competitive ELISA. Fourty six cancer sera were selected for inhibition ELISA. 
Out of fourty six, seven sera were from patients with stomatch cancer (Fig. 41). 
Among these, six sera were recognized ROS-HSA to a greater extent (66%, 
48%,45%,53%,41% and 51%) than native HSA (36%,29%,34%,35%,25% and 27%), 
respectively, remaining one sample showed negligible inhibition (23%) but higher 
than native HSA (19%). 
Only one sample of oral cancer was tested and it was found to recognize ROS-
HSA (55%) to a greater extent than native HSA (31%) (data not given). 
Among the eight samples from patients with lung cancer, two showed strong 
reactivity towards ROS-HSA (64% and 63%) than to its native form (38% and 37%), 
while five samples showed moderate inhibition to ROS-HSA (45%,52%,47%,50% 
and 40%) but higher than native HSA (24%,36%, 37%,33% and 28%), respecfively, 
whereas, remaining one serum showed negligible inhibition to either of inhibitors 
(Fig. 42). 
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TABLE 8 
Direct binding ELISA for the detection of antibodies against ROS-modified and 
native HSA in the sera of cancer patients 
Type of Cancer 
NHS' 
Stomach 
Oral 
Lung 
Chronic Myeloid 
Urinary bladder 
Breast 
Prostate 
Hepatocellular 
N« 
10 
7 
1 
8 
5 
7 
8 
1 
9 
Age(years)'' 
25.4 ±8.2 
45.2 ±7.2 
51.4±1.4 
61.2 ±0.7 
41.7 ±8.2 
44.5 ±10.6 
65.5 ±7.1 
68.2 ±6.2 
58.3 ±6.2 
ROS-HSA 
Mean ± SD' 
0.25 ± 0.12 
0.64*'±0.07 
0.64 
0.73^±0.16 
0.78^ ±0.09 
0.82*'±0.08 
0.77= ±0.23 
0.55 
0.80*'± 0.20 
"i;^v^^~" 
48 
42 
-
22 
11 
10 
30 
-
25 
Native HSA 
Mean ± SD' 
0.24 ±0.15 
0.37^±0.13 
0.36 
0.40*'±0.11 
0.32^ ±0.10 
0.29*'±0.16 
0.46° ±0.10 
0.39 
0.41*'±0.1 
cV 
62 
35 
-
27 
34 
55 
22 
-
12 
^Number of selected serum samples in each cancer populations 
''Mean age of cancer patients ± standard deviation 
'^ Absorbance at 410 nm ± standard error 
''Percentage of coefficient of variation 
^ H S represents normal human serum 
•p value < 0.05 
p^ value < 0.01 
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Figure 41. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HSA in the sera of patients with stomach cancer. The 
curves (A,T,o,«,B,n,A) represent sera from different patients. The 
microtitre plates were coated with ROS-HSA (10 |ag/ml). 
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Figure 42. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HSA in the sera of patients with lung cancer. The curves 
(A,T,o,•,(>,•,n,A) represent sera from different patients. The microtitre 
plates were coated with ROS-HSA (10 |ig/ml). 
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Of the five samples from chronic myeloid leukemia patients, the binding towards 
native HSA was lesser (35%,29%,31%,20% and 24%) than the ROS-HSA 
(52%,41%,50%,39% and 37%), respectively (Fig. 43). 
Seven samples were from patients with urinary bladder cancer (Fig. 44). Six 
showed higher higher recognition towards ROS-HSA (58%,46%,35%,47%,40% 
and 38%)), whereas native HSA was recognized with a lesser extent 
(39%),28%),32%),26%),33%) and 25%)), respectively. Remaining one serum neither 
showed inhibition with native nor with ROS-HSA. 
Among the eight sera from patients with breast cancer, six were found to 
recognize ROS-HSA to a greater extent (65%,44%,52%),48%,46% and 48%) than 
native HSA (38%,30%,29%,37%,35% and 27%), respectively, whereas remaining 
two showed negligible inhibition to either of the inhibitors (Fig. 45). 
One serum from patients with carcinoma of prostate, it was found to be more 
active to ROS-HSA (58%) than native HSA (34%) (data not given). 
Nine samples were from patients with liver cancer (Fig. 46). Six of these 
showed higher recognition towards ROS-HSA (64%,40%,39%,41%,51% and 
35%)), whereas native HSA was recognized to a lesser extent (36%,30%,3]%, 
35%o,34%) and 32%)), Remaining three serum samples were inactive for ROS-HSA 
and native HSA. These results were summarized in Table 9. 
To substantiate the above results, IgG were isolated from three active 
hepatocelluar carcinoma sera and three normal healthy subjects on a Protein-A 
Sepharose 4B affinity column. Competition ELISA (Fig. 47) was performed with 
isolated cancer IgG samples. ROS-damaged and native HSA were used as 
inhibitors. The microtitre plates were coated with the respective antigens. The 
average percent inhibition (± SD) at 20 [ig/ml of inhibitor concentration of three 
cancer IgG binding to ROS-HSA and native HSA was 67.43 ± 5.7 and 33.4 ± 3.4, 
respectively (Fig. 47), a p-value of <0.05 indicates significant difference in the 
binding of ROS-damaged and native HSA. 
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Figure 43. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HSA in the sera of patients with chronic myeloid 
leukemia. The curves (A ,O,« ,B ,A) represent sera from different patients. 
The microtitre plates were coated with ROS-HSA (10 ^ig/ml). 
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Figure 44. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HSA in the sera of patients with urinary bladder cancer 
The curves (A,o,«,i,A) represent sera from different patients. The 
microtitre plates were coated with ROS-HSA (10 ^g/ml). 
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Figure 45. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HS A in the sera of patients with breast cancer. The curves 
(A,T,o,«,0,B,n,A) represent sera from different patients. The microtitre 
plates were coated with ROS-HSA (10 |ag/ml). 
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Figure 46. Inhibition ELISA for the detection of antibodies against (a) ROS-HSA 
and (b) native HSA in the sera of patients with hepatocellular carcinoma. 
The curves ( A , T , O , » , 0 , B , D , A ) represent sera from different patients. 
The microtitre plates were coated with ROS-HSA (10 |ag/ml). 
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TABLE 9 
Competitive ELISA for the detection of antibodies against ROS-modified and native 
HSA in the sera of cancer patients 
Type of cancer 
Stomach 
Oral 
Lung 
Chronic Myeloid 
Urinary Bladder 
Breast 
Prostate 
Hepatocellular 
No. of selected sera 
tested 
7 
1 
8 
5 
7 
8 
1 
9 
Maximun percent 
ROS-HSA 
Mean ± SD 
46.7'±13T(28.0) 
55 
46.9'± 15.7(33.5) 
43.8 "±6.8 (14.5) 
41.0'±10.9(26.6) 
44.6''± 12.7(28.5) 
58 
38.0'± 13.7(36.0) 
inhibition at 20 fig/ml 
Native HSA 
Mean ± SD 
29.3'±6.1 (20.8) 
31 
30.6'±7.9 (25.8) 
27.8*'±5.9(21.2) 
29.0'±6.2(21.4) 
30.0'± 6.5(21.7) 
34 
26.7'±7.2 (27.0) 
The microtitre plates were coated with ROS-HSA (10 i^g/ml). The data in parenthesis 
shows percent coefficient of variation. 
'p value < 0.05 
ip value < 0.01 
17 
0.01 0.1 1 10 
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Figure 47. Inhibition of affinity purified cancer IgG binding to native and ROS-HSA. 
The inhibitors were ROS-modified HSA (•) and native HSA (•). The 
microtitre plates were coated with ROS-HSA (10 fig/ml). Each point 
represents a mean ± S.D. of three independent assays. 
118 
Band Shift Assay Using Cancer IgG 
The interaction of native and ROS-modified HSA with cancer antibodies was 
ascertained visually by gel retardation assay on PAGE under native condition. 
Figure 48 shows the binding of most active liver cancer IgG to ROS-HSA. The 
data showed difference in the mobility and corresponding decrease in the intensity 
of unbound antigen due to the formation of high molecular weight immune 
complexes. On increasing the concentration of IgG with constant amount of ROS-
HSA, the increase in the formation of high molecular immune complexes was 
clearly evident in wells. Native HSA with liver cancer IgG did not showed either 
visible retardation in the mobility of unbound antigen or the formation of immune 
complexes under identical experimental conditions (data not given). 
Detection of Carbonylated Serum Protein and Albumin in Cancer 
Patients 
Protein carbonyl groups as biomarker of oxidative stress and the oxidation of 
protein typically results in an increase in carbony contents. The data showed 
serum protein carbonyl contents were significantly (p < 0.01) increased in bladder 
cancer patients, compared with normal subjects. The average carbonyl contents 
(±SD) of three independent assays of cancer serum proteins and normal human 
serum proteins were 2.98 ± 0.09 and 2.22 ± 0.23 nmol/mg protein, respectively 
(Fig. 49). 
To investigate the extent of alterations in the biological properties of HSA in 
bladder cancer patients , HSA was isolated from bladder cancer patients (cancer-
HSA) and also from the normal subjects (NH-HSA) and their carbonyl contents 
were compared. The purity and homogeneity of cancer purified HSA was given in 
Figure 49. The average carbonyl contents (±SD) of three independent assays of 
cancer-HSA and NH-HSA were 2.2 ± 0.27 and 1.60 ± 0.20 nmol/mg protein, 
respectively (Fig. 49), a/? - value of < 0.01 indicates significant difference in the 
carbonyl contents of cancer-HSA and NH-HSA. The results were similar to those 
obtained with serum (Fig. 49). 
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Figure 48. Band shift assay of cancer IgG binding to ROS-HSA. Modified-HSA 
(50 |Jg each) was incubated with buffer (lane 1) and 25, 35 and 50 pg IgG 
through lanes 2 to 4, respectively for 2 h at 37°C and overnight at 4°C. Lane 
5 contains IgG (30 |jg) alone. Electrophoresis was performed on native 
PAGE on 7.5% gel with 2.5% stacking gel for 3 h at 80 V, 4°C. 
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Figure 49. Comparison of carbonyl contents in normal human serum proteins (bar 1), 
bladder cancer serum proteins (bar 2), HSA from normal human (bar 3) 
and HSA from bladder cancer patients (bar 4). Each histogram represents 
mean ± S.D. of three independent assays. 
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Figure 50. Elution profiles of purified HSA from the blood of bladder cancer patients (•) 
and commercial HSA (o) on Sephacryl S-200 HR column. Elution was 
performed with 0.06 M sodium phosphate buffer, pH 7.0, at flow rate of 15 
ml/h in 5 ml fractions. Protein in each fraction was monitored by the method 
ofLowryetal. (1951). 
Inset: Native PAGE of purified HSA and commercial HSA on 7.5 % gel. 
Lane 1 contains eluted commercial HSA (fraction no. 18) and lane 2 contains 
purified HSA (fraction no. 18) from cancer patients. The amount of protein 
in each case was 35 .^g. 
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Recognition of ROS-HSA by Circulating Type 1 Diabetes Mellitus 
Autoantibodies 
Sera from 31 type 1 diabetes patients and 10 normal human subjects were 
tested for binding to native and ROS-HSA by direct binding ELISA. Fifty percent 
sera (17/31) showed strong binding to ROS-HSA over native HSA at 1:100 serum 
dilution {p < 0.05). No appreciable binding was observed with the normal human 
sera. The average absorbance at 410 nm (±SE) of 17 diabetes sera binding to 
native and ROS-HSA was 0.51± 0.03 and 0.85 ± 0.06, respectively. Whereas, the 
average (±SE) of 10 normal human sera binding to native and ROS-HSA was 0.24 
±0.039 (Fig. 51). 
The binding specificity of type 1 diabetes autoantibodies was evaluated by 
inhibition ELISA using native and ROS-HSA as inhibitors (Figs. 52 to 54). The 
microtitre plates were coated with ROS-HSA. The average percent inhibition 
(±SD) of 17 diabetes sera binding to native and ROS-HSA was 19.9 ±5.7 and 
49.4 ± 9.3, respectively (Table 11). On comparing the inhibition values of native 
and ROS-modified HSA, ap - value of 0.01 indicates significant difference in the 
inhibitory capacity of these inhibitors. 
Band Shift Assay Using Diabetes IgG 
Band shift assay of native and ROS-HSA was performed using IgG of type 1 
diabetes patients. Constant amount of antigen was incubated with increasing 
concentration of diabetes IgG. The immune complexes were incubated at 37°C for 
2 h and overnight at 4°C. The samples were electrophosed on native PAGE. 
Figure 55 shows the binding of diabetes IgG to ROS-HSA. With the increase in 
IgG concentration there is a reduction in the mobility and intensity of the unbound 
antigen, this is due to the formation of high molecular weight immune complexes 
as clearly evident in wells. Native HSA with diabetes IgG did not showed either 
any visible retardation in mobility of unbound antigen or the formation of immune 
complexes under identical conditions (data not given). 
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Figure 51. Direct binding ELISA of 1:100 diluted type 1 diabetes serum samples. 
The microtitre plates were individually coated with HSA and ROS-HSA 
(10 |ig/ml). Binding of type 1 diabetes sera to native HSA (bar 2), and 
ROS-HSA (bar 3). Normal human serum (bar 1) with either of antigens. 
The numbers of diabetes serum samples were ] 7 (HSA, ROS-HSA) and 
normal human serum samples were 10 (HSA, ROS-HSA). Standard error 
has been indicated with each bar. 
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Figure 52. Inhibition ELISA of type 1 diabetes serum antibodies from six diabetes 
patients (a) (1,2,3) and (b) (4,5,6). The inhibitors used were native HSA 
(n,A,o) and ROS-HSA (•,A,«).The microtitre plates were coated with 
ROS-HSA (10 ng/ml). 
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Figure 53. Inhibition ELISA of type 1 diabetes serum antibodies from six diabetes 
patients (a) (7,8,9) and (b) (10,11,12). The inhibitors used were native 
HSA (•,A,o) and ROS-HSA (•,A,«).The microtitre plates were coated 
with ROS-HSA (10 ^ig/ml). 
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Figure 54. Inhibition ELISA of type 1 diabetes serum antibodies from six diabetes 
patients (a) (13,14,15) and (b) (16,17). The inhibitors used were native 
HSA (D,A,O) and ROS-HSA (•,A,«).The microtitre plates were coated 
with ROS-HSA (10 ^ g/ml). 
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TABLE 10 
Competitive inhibition of circulating antibodies in type 1 diabetes sera with HSA 
and ROS-HSA 
Maximum percent inhibition at 20 |^ g/ml 
DM serum Native HSA ROS-HSA 
1 3T2 4 0 
2 33.2 54.4 
3 20.1 39.4 
4 28.2 65.5 
5 35.7 53.6 
6 33.3 59.3 
7 27.2 61.1 
8 38.5 49.1 
9 27.4 54.0 
10 31.0 41.7 
11 20.4 62.2 
12 29.2 52.1 
13 31.3 42.3 
14 20.1 42.9 
15 19.4 35.6 
16 28.1 42.3 
17 31.8 36.2 
Mean ± S.D. 28.6 ±5.7 49.4 ±9.3 
(%C.V.) (19.9) (18.8) 
Microtitre plates were coated with ROS-HSA (10 f^ g/ml). Student's t evaluation of 
significance: HSA V modified HSA p<0.001. 
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Figure 55. Band shift assay of diabetes IgG binding to ROS-HSA. Modified-HSA 
(50 pg each) was incubated with buffer (lane 1) and 25,35,45 and 55 |Jg 
IgG through lanes 2 to 5, respectively for 2 h at 37°C and overnight at 
4°C. Lane 6 contains IgG (30 (Jg) alone. Electrophoresis was performed 
on native PAGE on 7.5% gel with 2.5% stacking gel for 3 h at 80 V, 4°C. 
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Estimation of Carbonyl Contents of Serum Proteins in Type 1 Diabetes 
Patients 
It is well known that the oxidation of serum proteins results an increase in 
carbonyl contents. The data showed serum protein carbonyl contents were 
significantly (p < 0.01) increased in diabetes patients, compared with normal 
human subjects. The average carbonyl contents (±SD) of three independent assays 
of diabetes serum proteins and normal human serum proteins were 3.2 ± 0.09 and 
2.2 ± 0.20 mnol/mg protein, respectively (Fig. 56). 
Further, to investigate the extent of alterations in the biological properties of 
HSA in diabetes patients, HSA was isolated from diabetes patients (DM-HSA) 
and also from the normal subjects (NH-HSA) and their carbonyl contents were 
compared. The average carbonyl contents (±SD) of three independent assays of 
DM-HSA and NH-HSA were 2.7 ± 0.14 and 1.60 ± 0.20 nmol/mg protein, 
respectively (Fig. 56), a p ~ value of < 0.01 indicates significant difference in the 
carbonyl contents of DM-HSA and NH-HSA. The results were similar to those 
obtained with serum (Fig. 56). 
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Figure 56. Comparison of carbonyl contents in normal human serum proteins (bar 1), 
type 1 diabetes serum proteins (bar 2), HSA from normal human (bar 3) 
and HSA from type 1 diabetes patients (bar 4). Each histogram 
represents mean ± S.D. of three independent assays. 
(Discussion 
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Reactive oxygen species (ROS) are continuously generated in cells by cellular 
metabolism and by exogenous agents but increases in their steady states are regarded 
to be responsible for a variety of pathological conditions, including cardiovascular 
diseases, cancer, SLE, and ageing (Ames et al., 1993; Ashok and Ali, 1998; Ashok 
and Ali, 2003; Khan et al., 2005; Mansoor et al., 2005). Hydroxyl radical is a highly 
reactive (Cheng et al., 2002) and toxic with one unpaired electron. It is formed 
through one electron reduction of hydrogen peroxide (Koppenaol and Liebman, 
1984). It is highly electrophillic in nature (Imamura and Hirao, 1979). Thus it is a 
powerful oxidizing agent. It is formed in living cells during physiological processes 
on after environmental stimulation. Since it is a highly reactive radical, once it is 
formed, it will react with various biomolecules. This then causes different biological 
damage eventually leading to many disease states. The OH readily reacts with a 
variety of biological macromolecules including protein, DNA, membrane lipids and 
cause protein-DNA crosslink's (Von Sonntag, 1987 a, b; Dizdaroglu, 1991; Halliwell 
and Aruroma, 1991; Cheng et al, 2002). Excess generation of reactive oxygen species 
have the ability, either directly or indirectly, to damage proteins, DNA and other cell 
biomolecules (Shacter, 2000). In fact, proteins are major targets for free radical attack, 
especially damaging in this respect is the hydroxyl radical. Protein oxidation, which 
results in functional disruption, is not random but appears to be associated with 
increased oxidation in specific proteins (Poon et al., 2006). A number of studies 
indicate a strong role for increases in protein oxidation as a primary cause of cellular 
dysfunction observed during aging and age related neuro-degenerative diseases 
(Tabner et al., 2001) such as Alzheimer's disease, Parkinson's disease, and possible 
some other protein conformational diseases. Inhibition of a wide array of enzyme 
activities have been reported (Arutyumova et al, 2003). Modification of structural 
protein can also lead to a loss of function. As for example, fibrinogen on exposure to 
ROS loses its ability to form a solid clot (Shacter et al, 1995). Oxidation of synovial 
fluid immunoglobulin cause aggregation and contribute to the etiology of rheumatoid 
arthritis (Chou, 2002). These disorders could be due to the formation of abnormal 
protein aggregates as a consequence of ROS damage. High levels of advanced 
oxidation products of protein have been implicated in the pathogenesis of chronic 
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rheumatic valve disease (Chiu-Braga et al., 2005). Recently, purified human 60 KDa 
Ro protein was found to be oxidatively modified leading to the formation of 
neoantigens which could in turn initiate autoimmunity (Scofield et al., 2005). 
Serum albumin is the most abundant serum protein whose redox modification 
modulates its physiologic function, as well as serves as biomarker of oxidative stress 
(Fabisiak et al, 2002). Many reported studies show the presence of elevated levels of 
oxidized albumin, in patients with diabetes mellitus type I (Oettl et al., 2005) and type 
2 (Suzuki et al, 1992; Oettl et al, 2005), aging (Oettl et al, 2005; Era et al, 1995), 
patients with chronic hepatifis C (Rigamonti et al, 2003; Jain et al, 2002), oxidized 
albumin is a reliable maker of oxidative stress in hemodialysis patients (Mera et al, 
2005; Soejima et al, 2004) and alteration of redox state of HSA is also seen in 
patients under anesthesia and invasive surgery (Hayakawa et al, 1997) and many 
other diseases. It has been well documented that HSA is quite vulnerable to reactive 
oxygen species (Davies, 1987; Anraku et al, 2001; Carballel et al, 2003). Therefore, 
HSA is continuously exposed to oxidative stress, so that alterations of the 
conformation and function of HSA could occur, resulting in modification of its 
biological properties. 
SLE is an autoimmune disease characterized by the presence of circulating 
anti-DNA autoantibodies. Autoantibody production in lupus has been attributed to 
either selective stimulation of autoreactive B cells by self antigens or antigens cross-
reactive with self (Hardin et al, 1986). Numerous modified forms of DNA have been 
found to be immunogenic and are recognized by SLE anti-DNA antibodies (Arif and 
Ali, 1996; Arjumand et al, 1995; Moinuddun and Ali, 1994). According to Diamond 
et al (1992) and Hardin (1986) the persistence of anfi-DNA antibodies in SLE 
patients, despite systems to suppress self-recognition, suggests that the response is 
driven by an antigen resembling native DNA, together with somatic mutations in the 
variable regions within B cells. 
Free radical-mediated damage has been implicated in the pathogenesis of SLE 
(Evans, 2000; Ahsan et al, 2003; Scofield et al, 2005). The binding diversity of 
lupus autoantibodies to a whole spectrum of modified nucleic acid conformers (Ali et 
al, 1991; Alam and Ali, 1992; Alam., el al, 1992; Arif ef al, 1994; Arjumand and 
Ali, 1994; Klinman et al, 1994; Moinuddin and Ali, 1994; Ahmad et al, 1997; Grag 
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and Ali, 1998; Dixit and Ali, 2004; Mansoor et ah, 2005) seems to be enormous. 
Recently, lupus associated 60-KDa Ro protein is modified with the lipid oxidation 
product 4-hydroxy-2-noneral (HNE) increases antigenicity and facilitates epitope 
spreading (Scofield et al., 2005) and antibodies to some other stress protein are also 
found in SLE (Ahsan et al., 2003; Waris and Alam, 1998; Eggeleton, 2003, Poon et 
al., 2006). These defective protein and DNA are the indication of oxidative stress in 
SLE. 
Despite the power of modern molecular approaches and persisting 
investigative efforts, lupus remain remains an enigmatic disorder (Perl, 2004) or the 
agent (or agents) triggering this autoimmune response remain to be identified. Patients 
with SLE have a diverse array of anti-nuclear autoantibodies, but the cellular and 
molecular mechanisms that are responsible for the production of anti-nuclear 
antibodies in this disease and the way in which these antibodies participate in tissue 
destruction remain highly controversial (Ravirajan et al., 2001). 
In the present study commercially available human serum albumin (HSA) was 
modified by hydroxyl radical, generated by the UV irradiation of hydrogen peroxide 
at 254 nm. Hydroxyl radical caused extensive damage to HSA resulting in 
hyperchromicity of the spectral curve of ROS-HSA as compared to its native 
analogue. This could be attributed to the structural alteration in aromatic amino acids 
contributing to UV light absorption. UV differential spectral curve of 'OH-modified 
HSA with reference to native HSA showed two positive peaks at 220 nm and 280 nm 
indicating hyperchromicity of modified HSA. This could be due to the modification 
of chromphoric groups, modification of aromatic amino acid residues of HSA or due 
to structural alteration. 
HSA modification was further confirmed by far and near UV region circular 
dichroic spectroscopy. Increase in the ellipticity values of 'OH-damaged HSA in far 
and near UV region of circular dichroic spectrum indicated a substantial loss of 
secondary as well as tertiary structure of HSA. 
HSA contains only one tryptophan residue (Trp-214) which is present in 
domain-II, oxidation of tryptophan residue upon ROS modification was confirmed by 
the decrease in fluorescence intensity after exciting the protein at 295 nm, clearly 
indicating that the conformational changes have occurred in domain-II of HSA. These 
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conformational changes were further confirmed by exciting the protein at 280 nm. 
The data of SDS-PAGE under reducing and non-reducing conditions reiterate the 
above results that substantial modification has been found on exposure of HSA by 
OH radical. 
Thermal denaturation profile showed unfolding of ROS-modified HSA 
required high temperature as compared to native HSA. The results indicates that 
stability of HSA increases upon ROS modification as ROS-HSA required high 
temperature to melt. 
HPLC anion exchange analysis showed that higher NaCl concentration was 
required to elute ROS-HSA as compared to native HSA. The isoelectric point of HSA 
has probably changed upon ROS modification, so that it binds more tightly to an 
anion exchanger as compare to its unmodified form. 
Protein carbonyl content is actually the most general indicator and by far the 
most commonly used marker of protein oxidation (Berlett and Stadman, 1997; 
Chevion et al, 2000; Shacter, 2000; Beal, 2002) and accumulation of protein 
carbonyls has been observed in many human diseases (Dalle-Dome et a\., 2003; 
Yilmaz et al, 2003). Oxidatively induced carbonyl contents in ROS-modified HSA 
were determined with increasing H2O2 concentration under constant UV irradiation. 
The OH generation was observed to be H2O2 concentration dependent and carbonyl 
formation increased with the increase of H2O2. Generation of'OH radical was further 
confirmed using mannitol and DMSO as the specific quenchers of OH radical. 
Inhibition in the formation of protein carbonyl contents were observed when mannitol 
and DMSO were added to the 'OH generating system. 
Both native and OH-modified HSA were found to be immunogenic in rabbits 
as revealed by direct binding and inhibition ELISA, immunodiffusion, quantitative 
precipitin titration and gel retardation assay. However, 'OH-modified HSA was found 
to be more immunogenic as compared to native HSA. Band shift assay clearly 
demonstrated the absolute specificity of the purified immune IgG towards their 
respective immunogens. Antigenic specificity of purified IgG was confirmed by 
inhibition ELISA. A maximum of 90% inhibition of anti-HSA IgG with immunogen 
as inhibitor was observed at 20 |Jg/ml and 50% inhibition was achieved at 0.8 |Jg/ml. 
A maximum of 97%o inhibition in the binding of anti-ROS-HSA IgG with immunogen 
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as an inhibitor at 20 [Jg/ml was observed and only 0.2 (Jg/ml of immunogen was 
required for 50% inhibition. Apparent antibody affinity constant for native and ROS-
HSA were also evaluated by Langmiur plot using quantitative precipitin titration, and 
it was found to be much better for ROS-HSA than to native HSA. The data showed 
that although native HSA was found to be immunogenic in experimental animals but 
HSA modified with OH was found to be more immunogenic, clearly indicating that 
modification of HSA by ROS have generated potential neoepitopes against which 
antibodies are raised . 
The notable feature of experimentally induced antibodies against ROS-
modified HSA was polyspecificity towards nucleic acid conformers. Plasmid DNA 
and ROS modified conformers of plasmid DNA and chromatin were found to be an 
effective inhibitors of induced antibody-immunogen interaction. Induced antibodies 
against native HSA showed negligible binding to the above mentioned nucleic acid 
antigens. Polyspecificity behavior of induced antibodies against native and ROS-
modified HSA was also tested against various blood proteins and their ROS-
conformers by inhibition ELISA. The induced antibodies against native as well as 
ROS-modified HSA showed negligible binding towards blood proteins and their 
ROS-conformers. In order to further confirm that the induced anti-ROS-HSA IgG has 
binding affinity towards nucleic acid antigens and ROS-conformer of nucleic acids, 
band shift assays were performed using native ctDNA and ROS-DNA as antigens. 
The results revealed that anti-ROS-HSA IgG showed the binding affinity towards 
native and ROS-DNA. Whereas, anti-HSA IgG did not showed binding towards 
native and ROS-DNA. Analysis of the data indicates that anti-ROS-HSA antibodies is 
immunogen specific and show cross-reactivity with various native and ROS-modified 
nucleic acid conformers might be due to sharing of common antigenic determinants. 
It was thought worthwhile to investigate the binding characteristics of 
naturally SLE autoantibodies to ROS-damaged HSA. Autoantibodies from fifty nine 
different SLE sera were screened by direct binding and inhibition ELISA. Of these, 
52.5% sera showed prefentially high binding towards ROS-HSA as compare to native 
HSA (p<O.OQ\). No detectable antibody activity was found in normal human sera. 
The results of competition inhibition ELISA supported hy p values and 
correlation coefficients clearly indicate high recognition of ROS-HSA over native 
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HSA by circulating SLE autoantibodies. Isolated IgG from SLE sera showed similar 
results. The result is also supported by gel retardation assay. The apparent affinity 
constants reiterated the results obtained by ELISA and band shift assay. 
The oxidation of a protein typically results in an increase in carbonyl contents. 
This increase is due to the oxidation of lys, arg, pro or other amino acid residues. In 
short, protein carbonyl groups are the biomarker of oxidative stress (Dalle-Dome et 
al., 2003). In human plasma, all amino acids in the protein are susceptible to oxidative 
modification by oxidants such as hydroxyl radicals and hypochlorous acid (Levine et 
al., 1994). Present data showed total serum protein carbonyl contents were 
significantly {p < 0.01) increased in SLE patients compared with normal subjects. 
Further, to investigate the extent of alterations in the biological properties of HSA in 
SLE patients. HSA was isolated from five SLE pafients (SLE-HSA) and also from 
three normal subjects (NH-HSA) and their carbonyl contents were compared. A p -
value of 0.05 indicates significant difference in the carbonyl contents of SLE-HSA 
and NH-HSA. The present data is in full agreement with the view, that normal-HSA 
offered significant protection against free radicals (Wayner et al., 1985; Halliwell and 
Gutteridge, 1990) compared to patients-HSA. The above mentioned results suggested 
that SLE patients with increased oxidative stress, the oxidative modification of plasma 
proteins is greatly enchanced. Since the most abundant protein of plasma is albumin, 
it is likely to be extensively damaged and might be responsible for the pathological 
conditions associated with SLE. 
Increased levels of circulating antibodies and autoantibodies have been 
reported in sera of patients with cancer (Tannenberg et al., 1973; Whitehouse, 1973; 
Wasserman et al., 1975; Anderson et al., 1988; Chagnaud et al., 1992; Faiderbe et 
al.., 1992; Becker et al., 1994; Ashok and Ali, 1998). Protein oxidation, DNA and 
lipid peroxidation possess a major impact in carcinogenesis (Yilmaz e( al., 2003). In 
the present study, the presence of autoantibodies reactive towards native and ROS-
modified HSA in different cancer patients was also studied. The study comprised of 
eighty one sera from patients with various types of malignancies including stomach, 
oral, lung, CML, bladder, breast, prostate and hepatocellular carcinoma. Of these, 
57% sera showed prefentially high binding towards ROS-HSA as compared to native 
HSA. Further, liver cancer IgG of three most active cancer sera and three from the 
137 
normal subjects were also tested for recognition to native and ROS-HSA, similar 
results were obtained, d. p - value of 0.05 indicates significant difference in the 
binding of native and ROS-HSA. The binding of native and ROS-HSA with 
circulating cancer autoantibodies was further substantiated by band shift assay. 
Carbonyl contents in the serum of cancer patients were found to be significantly 
(p<0.01) higher than in the serum of normal healthy subjects. Similar results were 
obtained with isolated HSA from cancer patients and HSA from the normal healthy 
subjects. These results are the indication of the presence of reactive oxygen species 
induced HSA damage in cancer patients. Presence of autoantibodies in cancer sera 
reactive towards ROS-HSA, may be attributed to OH induced damaged to HSA 
rendering it immunogenic. The autoantibodies may, therefore be raised primarily 
against 'OH modified HSA and cross react with native HSA to a lesser extent. 
Oxidative stress plays a central role in the onset of diabetes mellitus as well as 
in diabetes associated complications (Phillips, 2004). Various studies have shown that 
diabetes is associated with increased formation of free radicals and decrease in 
antioxidant potential. This leads to oxidative damage of cell components such as 
proteins, lipids and nucleic acid. In type 1 diabetes mellitus, there is increased 
oxidative stress (Nazirogilu and Butterworth, 2005). Hyperglycemia increases the 
production of ROS and decreases their scavenging by various mechanisms. Such an 
increase of ROS may disturb or modify various cellular functions and alter gene 
expression due to oxidative stress. High glucose induced mitochondrial over 
production of ROS (Nishikawa et al, 2000) and abnormal activation of NAD (P) H 
oxidase (Kim, et al, 2002; Inoguchi et al., 2003) are thought to be the major sources 
of ROS associated with hyperglycemia, while sustained hyperglycemia may also 
decrease radical scavenging capacity (Yan and Harding, 1997; Kashiwagi et al, 1996). 
In the present study, the presence of autoantibodies against native and ROS-modified 
HSA in the sera of type 1 diabetes mellitus was tested. Thirty one sera from patients 
having post prandial blood sugar level greater than 200 mg/dl were collected. Of 
these, seventeen sera showed prefentially strong binding to ROS-HSA over native 
HSA (p<0.05). Inhibition ELISA results showed the similar results. Band shift assay 
further substantiated the increased binding of ROS-HSA to diabetes autoantibodies. 
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Increased oxidative stress in diabetic patients may lead to protein oxidation 
(Telci et al, 2000). The conversion of protein to protein carbonyl (PCO) derivatives 
occurs via direct oxidation by ROS, with the eventual formation of oxidized amino 
acids (Carrad et a/., 2002; Stadtman and Levine, 2000). Oxidative protein damage 
cannot be repaired, except for the oxidation of methionine and cytseine (Stadtman, 
2002). These oxidations cause irreversible modifications in protein. The structure and 
activity of oxidized proteins change profoundly in comparison with their native forms. 
Oxidative modification of proteins in vivo may affect a variety of cellular functions. 
The best marker for intracellular oxidative stress-dependent cellular damage is the 
PCO content. The unique advantage of the carbonyl measurement as a good marker of 
oxidative stress is the fact that it covers a much wider range of oxidative damage than 
other markers do (Cakatay et al., 2003; Carrard et al., 2002; Evans et al., 1999; 
Reznick and Packer, 1994). Present data showed total serum protein carbonyl contents 
were significantly {p < 0.01) increased in diabetes patients compared with normal 
subjects. To investigate the extent of alterations in the biological properties of HSA in 
diabetes patients, HSA was isolated from three type 1 diabetes patients (DM-HSA) 
and also from three normal subjects (NH-HSA) and their carbonyl contents were 
compared. Ap - value of 0.01 indicates significant difference in the carbonyl contents 
ofDH-HSA and NH-HSA. 
Thus, by employing various immunological techniques, the data clearly 
demonstrates a substantial increase in the recognition of ROS damaged HSA over 
native HSA by naturally occurring autoantibodies of type 1 diabetes mellitus. 
The enhanced recognition of ROS damaged HSA by SLE, type 1 diabetes and 
various cancer sera demonstrates the possible participation of damaged albumin in the 
above mentioned diseases pathogenesis. Thus, it appears that ROS modification on 
HSA lead epitope spreading that are recognized by circulating autoantibodies in SLE 
and type 1 diabetes patients and these epitope spreading are also recognized by 
various cancer antibodies. It infact oxidative processes are the important factors that 
induce autoimmunity in the clinical scenario, it may be possible to prevent the 
development of the above mentioned diseases in genetically susceptible individuals 
by administration of antioxidants or other dietary manipulations to decrease formation 
of ROS-HSA/ oxidative-by-products. 
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Based on the above studies, the following conclusions can be drawn: 
1. Reactive oxygen species modification of human serum albumin resulted the 
loss of significant proportion of secondary as well as tertiary structure of 
native protein, significant loss of tryptophan fluorescence intensity and 
significant increase in the protein carbonyl contents. 
2. ROS-modified HSA was highly immunogenic in experimental animals as 
compared to native HSA. 
3. Induced antibodies were highly specific for the immunogen. 
4. The induced antibodies against ROS-HSA showed polyspecificity. These 
antibodies showed significant binding with various nucleic acid conformers, 
whereas induced antibodies against native HSA was found to have limited 
antigen recognition. 
5. SLE autoantibodies showed preferential binding to ROS-modified HSA over 
native HSA. 
6. ROS-modified HSA presents discriminating antigens for the binding of SLE 
autoantibodies. It is suggested that ROS-HSA might be challenging the 
immune system, leading to autoantibody production. 
7. Antibodies in sera of various cancer patients were found to be more specific 
for ROS-HSA than for its native analogue. 
8. Autoantibodies in the sera of various type 1 diabetes patients recognized ROS-
HSA to great extent as compared to native HSA. 
9. Total serum proteins and purified HSA from SLE, type 1 diabetes and cancer 
patients were found to be oxidatively modified as evident by the significant 
increase in the carbonyl contents. 
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